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Abstract 
Antimicrobial peptides are a critical part of the innate immune system of the skin. 
Epidermal keratinocytes (KCs) express numerous such peptides which establish a 
protective barrier to invading microorganisms. The antimicrobial peptide S100A7c 
(psoriasin) is the most efficient killer of Escherichia coli, but the regulatory mechanism of 
S100A7c in KCs was unclear. We investigated the responsiveness of S100A7c expression 
to microbial components and found that flagellin, a ligand for Toll-like receptor (TLR) 5, 
strongly induced the expression of S100A7c whereas all other TLR ligands had no 
significant effect on S100A7c mRNA expression. Supernatant from wild-type E. coli, but 
not from a flagellin-deficient E. coli strain (∆FliC), strongly induced S100A7c mRNA as well 
as protein expression, identifying flagellin as the principal S100A7c inducing component of 
E. coli supernatant. In line with this finding, small interference RNA-mediated knock-down 
of TLR5 expression suppressed the ability of KCs to up-regulate S100A7c mRNA and 
protein expression in response to flagellin or E. coli supernatant suggesting that this up-
regulation is mediated via TLR5 signaling.  
RNase 7, another antimicrobial peptide expressed by KCs, not only contributes to the 
surface ribonuclease activity of human skin but also participates to the cutaneous 
antimicrobial defense. RT-PCR screening revealed that in addition to RNase 7 epidermal 
KCs expressed RNases 1, 4 and 5 as well as RNase inhibitor (RI), an endogenous protein 
that blocks the ribonucleolytic activity of RNases. In vitro assays demonstrated that RI 
suppresses the ribonuclease activity of stratum corneum (SC) RNases as well as the anti-
bacterial activity of RNase 7 and the Candida-cidal activity of RNase 5. RI is strongly 
expressed by the granular layers of the epidermis whereas it was not detectable in the SC. 
Co-incubation experiments with SC extracts led to degradation of RI protein which could 
be prevented by the serine protease inhibitor aprotinin. This finding suggests the existence 
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of a physiological mechanism of RI breakdown in the SC to facilitate skin surface 
ribonuclease and antimicrobial activity. 
Taken together these data bring new insights into the regulatory mechanisms of skin-
derived antimicrobial peptides and demonstrates the importance of SC proteolysis activity 
for establishing appropriate RNase-dependent antimicrobial functions of the skin. 
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1. Introduction 
1.1. The structure of human skin 
Skin is the outer covering of living organisms. It functions as a protective barrier 
against the external environment; as an important factor in temperature regulation; as a 
sensory organ; and as an organ of metabolism that has synthesizing, excretory, and 
absorptive functions. Human skin is composed of the epidermis, which is the outermost 
epithelial layer of the skin and serves as a direct barrier to the environment; the subjacent 
dermis, which harbors skin vessels, skin nerves and skin appendage; and the subcutis 
consisting mainly of fat cells (Bolognia J.L. et al., 2008). 
The epidermis is a stratified epithelium which is formed of keratinocytes (KCs) through 
terminal differentiation, but also harbors other cell types i.e. melanocytes, Langerhans 
cells and Merkels cells (Bolognia J.L. et al., 2008). KCs originate from a stem-cell pool in 
the basal epidermal layer and undergo progressive terminal differentiation as they move 
outward, finally forming the stratum corneum (SC). On simple morphological grounds, the 
epidermis can be divided into four distinct layers: stratum basale, stratum spinosum, 
stratum granulosum and SC (Bolognia J.L. et al., 2008).  
Beneath the epidermis, the vascularised dermis provides structural and nutritional 
support. The dermis is tightly connected to the epidermis by a basement membrane. It 
also harbors many nerve endings that provide the sense of touch and temperature. It 
contains the hair follicles, sweat glands, sebaceous glands, apocrine glands and blood 
vessels. The blood vessels in the dermis provide nutrition and removal of waste to its own 
cells as well as the stratum basale of the epidermis (Bolognia J.L. et al., 2008).  
The subcutis lies below the dermis and serves mainly for fat storage and insulation. It 
attaches the skin to the underlying bone and muscle (Bolognia J.L. et al., 2008). 
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1.2. Skin-derived antimicrobial peptides: establishing a defense-line 
against invading microorganisms 
In 1987, Michael Zasloff showed that frog skin protects itself against infections by the 
release of antimicrobial peptides called magainins (Zasloff, 1987), which exhibit a broad-
spectrum of antimicrobial activity. These observations led other investigator to search for 
the presence of antimicrobial proteins also in human skin (Schröder and Harder, 2006).  
Normal human skin is colonized by large numbers of microorganisms. Most of these 
microorganisms are commensals which live on the skin surface without causing disease. 
In addition to the normal skin flora, the skin is exposed to pathogenic microorganisms. 
However, these pathogens rarely survive long enough to produce clinical infection. 
Whereas the mechanical barrier function of normal skin plays an important role in the 
clearance of pathogens from the skin surface (Schröder and Harder, 2006), there is 
evidence from a number of studies that skin-produced antimicrobial proteins also play an 
important part in the elimination of such pathogens (Gläser et al., 2005; Harder et al., 
1997; Harder and Schröder, 2002; Lee et al., 2008; Murakami et al., 2002; Schittek et al., 
2001). 
In the past 10 years a number of skin-derived antimicrobial peptides have been 
discovered in human skin as discussed below. 
 
1.2.1. Lysozyme 
Lysozyme was the first antimicrobial protein found in skin (Ogawa et al., 1971). It 
catalyses the hydrolysis of the peptidoglycan layer in the bacterial cell wall. The 
antimicrobial activity of lysozyme is mainly against Gram-positive bacteria, e.g. 
Staphylococcus aureus, but it is also active against Gram-negative bacteria, e.g. 
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Escherichia coli (Ellison, III and Giehl, 1991) or Pseudomonas aeruginosa (Cole et al., 
2002), suggesting that it might control the growth of bacteria in healthy skin. 
Immunoreactive analysis demonstrates that lysozyme is mainly located in the 
cytoplasm of cells in the spinosum layers of the epidermis. All parts of the eccrine sweat 
glands as well as pilo-sebaceous follicle cells, hair bulb and follicle sheat cells were also 
positive for lysozyme, but not the hair-shaft (Papini et al., 1982). Since immunoreactive 
lysozyme is absent in the SC and skin washing fluid (Ogawa et al., 1971), its contribution 
to cutaneous host defense is still unclear.  
 
1.2.2. Dermcidin 
Dermcidin appears to be the principal sweat antimicrobial peptide (Schröder and 
Harder, 2006). It is expressed as a precursor which is then proteolytically cleaved to a 47- 
amino acid containing peptide resulting in dermcidin-1 (DCD-1). This peptide performs 
antimicrobial activity against S. aureus, Enterococcus faecalis, E. coli as well as Candida 
albicans at low micromolar concentration (1–10 µg/ml). Therefore suggesting that 
dermcidin may play a role in the regulation of human skin microflora (Schittek et al., 2001). 
The antimicrobial activity of dermcidin is maintained at high salt concentrations and over a 
broad pH range, which are similar to the conditions in human sweat (Schittek et al., 2001).  
Dermcidin is specifically and constitutively expressed in sweat glands, secreted into 
the sweat and transported to the epidermal surface (Schittek et al., 2001). Interestingly, 
dermcidin protein expression is not induced in human epidermal KCs under inflammatory 
skin conditions (Rieg et al., 2004). It has been shown that the amount of several DCD-
derived peptides in sweat of patients with atopic dermatitis is significantly reduced which 
could be a reason for pronounced colonization with S. aureus and recurrent bacterial skin 
infections in this patients (Rieg et al., 2005). 
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1.2.3. Cathelicidin  
Human cathelicidin is produced as a preproprotein of 18 kDa (human cationic 
antimicrobial protein with a molecular size of 18 kDa; hCAP-18) which is proteoliticlly 
processed by the serine protease proteinase 3, yielding the C-terminal 37-amino acids 
containing the antimicrobial active LL-37 peptide (Sorensen et al., 2001). Apart from the C-
terminal peptide LL-37, the cathelin domain of hCAP-18 is also antimicrobially active as 
demonstrated with recombinant cathelin (Zaiou et al., 2003). In vitro, LL-37 inhibits the 
growth of a variety of Gram-negative (E. coli, P. aeruginosa, Salmonella typhimurium) and 
Gram-positive bacteria (Lysteria monocytogenes, S. aureus, Staphylococcus epidermidis 
and vancomycin-resistant Enterococci) at micromolar concentrations. It is also active 
against several bacteria at high salt conditions (Turner et al., 1998). 
Cathelicidin is expressed in circulating neutrophils and myeloid bone marrow cells, in 
epithelia of the skin, airways, mouth, tongue, esophagus, intestine, cervix, vagina, 
epididymis and in testis (Gallo et al., 1997; Gudmundsson et al., 1996; Malm et al., 2000; 
Zaiou and Gallo, 2002; Zanetti, 2005). Like dermcidin, the human cathelicidin is also 
expressed in eccrine glands and duct cells. Immunoreactive LL-37 is localized in both the 
eccrine secretory glands and ducts, where it is found to be diffusely located in the 
cytoplasm of the secretory gland, and also located in the ductal epithelium (Murakami et 
al., 2002). This observation and the antimicrobial activity of LL-37 against various bacteria 
indicate that LL-37 might also contribute to the antimicrobial activity of human sweat 
(Murakami et al., 2002). 
The expression of cathelicidin in skin seems to be tightly regulated because it is only 
expressed in KCs of inflamed skin but not of healthy skin (Frohm et al., 1997). It was also 
demonstrated that cathelicidin expression was up-regulated after skin injury (Dorschner et 
al., 2001). In an in vitro model, the highest level of cathelicidin is attained at 48 hours after 
injury (Heilborn et al., 2003). It has been demonstrated that 1,25-dihydroxyvitamin D(3), 
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induces the expression of cathelicidin in human KCs (Wang et al., 2004; Weber et al., 
2005). This induction was also observed in monocytes and neutrophils (Wang et al., 
2004). The mechanism for this up-regulation occurs via a consensus vitamin D response 
element (VDRE) in the promoter of cathelicidin which is bound by the vitamin D receptor 
(VDR) (Gombart et al., 2005). Interestingly, the murine homologue to human cathelicidin 
(cathelicidin-related antimicrobial peptide; CRAMP) is not induced by vitamin D because of 
the absence of VDRE in murine CRAMP promoter (Gombart et al., 2005). 
The in vivo relevance of cathelicidin in cutaneous host defense has been 
demonstrated in a mouse model. Mice deficient in the expression of CRAMP were more 
susceptible to skin infections caused by group A Streptococcus (GAS) (Nizet et al., 2001). 
These mice were also susceptible to urinary tract infections caused by uropathogenic E. 
coli (Chromek et al., 2006). 
 
1.2.4. Skin-derived ribonucleases (RNases) 
The human RNase A superfamily consists of thirteen members which are encoded by 
unique genes located on chromosome 14q11.2. Eight genes (RNases 1 to 8) of this family 
encode for ribonucleolytically active proteins which are relatively small in size (~15 kDa) 
and to varying degrees catalytically active against standard RNA substrates (Dyer and 
Rosenberg, 2006). Apart from their ribonuclease activity, some members of this family 
have antimicrobial properties as well (Domachowske et al., 1998; Lehrer et al., 1989; 
Rudolph et al., 2006). RNase 2 has antiviral activity, especially against the respiratory 
syncytial virus (Domachowske et al., 1998). RNase 3 performs antibacterial activity against 
S. aureus and E. coli (Lehrer et al., 1989) and has also killing activity toward the helminth 
Schistosoma mansoni (Ackerman et al., 1985). RNase 5 is active against C. albicans and 
Streptococcus pneumoniae (Hooper et al., 2003). RNase 7 and RNase 8 exhibit a broad 
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spectrum of antimicrobial activity against both Gram-negative and Gram-positive bacteria 
(Harder and Schröder, 2002; Rudolph et al., 2006). To date, among members of these 
family, only RNase 5 (this dissertation) and RNase 7 were detected in the SC (Harder and 
Schröder, 2002), which are discussed below. 
RNase 7: Analysis of healthy human skin for the presence of endogenous 
antimicrobial proteins led to the discovery of a 14.5 kDa antimicrobial ribonuclease termed 
RNase 7 (Harder and Schröder, 2002). The capacity of RNase 7 to digest RNA identifies 
this molecule as a part of the RNase activities found on human skin, making it necessary 
to take special precautions when performing experiments with RNA (i.e. by wearing 
gloves) (Harder and Schröder, 2002). RNase 7 is present at 4–8 µg/g of dry weight healthy 
SC. In contrast, 10–25 µg/g could be recovered from psoriatic-scale material, suggesting 
that RNase 7 might be inducible (Harder and Schröder, 2002; Harder and Schröder, 
2005b). RNase 7 exhibits a broad spectrum of antimicrobial activity against both Gram-
negative and Gram-positive bacteria and the yeast C. albicans. For unknown reasons 
RNase 7 is extremely effective at killing a vancomycin-resistant strain of E. faecium 
already at 20 nM concentrations (Harder and Schröder, 2002). It was suggested that 
RNase 7 antimicrobial activity is due to binding to bacterial membrane which renders the 
membrane permeability and causes pore formation into the membrane of bacteria. 
Additional studies have revealed that antimicrobial and ribonuclease activities of RNase 7 
are independent of each other. The antimicrobial activity of recombinant RNase 7 is still 
retained at 4°C (Huang et al., 2007). The pro-inflammatory cytokines interleukin (IL) -1β, 
interferon (IFN) -γ and to a lesser degree also tumour necrosis factor (TNF) -α induced 
RNase 7 messenger RNA (mRNA) expression in KCs. Primary KCs treated with heat-
killed bacteria such as P. aeruginosa and to a lesser degree S. aureus, E. coli, and S. 
pyogenes also induced RNase 7 expression in KCs (Harder and Schröder, 2002). 
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RNase 5: RNase 5, also known as angiogenin, has been implicated in blood vessel 
formation (Fett et al., 1985). A recent study revealed antimicrobial function for RNase 5 
toward C. albicans and S. pneumoniae in vitro (Hooper et al., 2003). RNase 5 is secreted 
by reconstructed human epidermis (Rendl et al., 2001), but its contribution to the innate 
immunity of the skin is unknown. 
Ribonuclease inhibitor: Ribonucleas inhibitor (RI) is a leucin-rich repeat protein with 
the shape of a horseshoe (Kobe and Deisenhofer, 1993). It constitutes about 0.1% of the 
total protein in the cytosol of mammalian cells (Leland and Raines, 2001). RI binds with 
high affinity to several members of the RNase A superfamily (Iyer et al., 2005; Johnson et 
al., 2007; Maeda et al., 2002; Papageorgiou et al., 1997; Shapiro et al., 1986; Shapiro and 
Vallee, 1987), thus inhibiting their enzymatic activity. Remarkably, RI binds to a series of 
RNases, i.e. RNases 1-6 which share low sequence identity (Papageorgiou et al., 1997). It 
is of particular importance for cells to protect themselves from exogenous RNases, since 
extracellular RNases which enter the cytosol and evade the binding of RI, catalyze 
cleavage of cellular RNA, eventually leading to cell death (Leland and Raines, 2001). 
RI is strongly expressed by the granular layer of the epidermis (this dissertation); 
however, at the time of our investigation it was unclear whether RI has the potential to 
block the microbicidal activities of RNase 5 and RNase 7, which are both expressed by 
KCs and are present in the SC. 
 
1.2.5. Human defensins  
Defensins are cysteine-rich, cationic peptides with β-sheet structures that are 
stabilized by three intramolecular disulphide bonds between the cysteine residues (Ganz, 
2003). Mammalian defensins are classified into three subfamilies, the α-, β- and θ-
defensins, which differ in their distribution of and disulphide links (bonds) between the six 
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conserved cysteine residues. The disulphide linkages of cysteine residues in α-defensins 
are between Cys1–Cys6, Cys2–Cys4 and Cys3–Cys5, whereas in β-defensins, the linkages 
are Cys1–Cys5, Cys2–Cys4 and Cys3–Cys6. By contrast, θ-defensins have a circular 
structure with the cysteine residues linked as Cys1–Cys6, Cys2–Cys5 and Cys3–Cys4  
(Ganz, 2003).  
Leukocytes and epithelial cells are the main sources of mammalian defensins. So far, 
six human α-defensins have been identified (Klotman and Chang, 2006). Although α-
defensins are found in granulocytes, at mucosal surfaces and in various tissues (Agerberth 
et al., 2000; Cunliffe, 2003; Fellermann and Stange, 2001; Hein et al., 2002), but there is 
no evidence of their expression by KCs (Harder and Schröder, 2005b).       
Twenty eight human β-defensins (hBDs) have been identified by gene-based 
searches, but only six hBDs (hBD-1, -2, -3, -4, -5 and -6) are expressed mainly by 
epithelial cells (Ganz, 2003; Yang et al., 2004). Whereas hBD-1 is constitutively expressed 
by epithelial cells, expression of hBD-2 and hBD-3 can be induced by viruses, bacteria, 
microbial products and pro-inflammatory cytokines (Schröder and Harder, 2006). The 
mechanism(s) by which microorganisms are killed and/or inactivated by defensins is not 
understood completely. However, it is generally believed that killing is a consequence of 
disruption of the microbial membrane. For example hDB-2 can aggregate to form ‘channel-
like’ pores leading to disruption of membrane integrity and function, which ultimately 
causes the lysis of microorganisms (Hoover et al., 2000; Sahl et al., 2005; Yang et al., 
2002). Below are listed the β-defensins expressed by human KCs. 
HBD-1 is the first discovered human β-defensin. It was originally isolated from human 
blood filtrates as a novel peptide with significant sequence homology to bovine β-defensins 
(Bensch et al., 1995). Mature hBD-1 is a small, cationic peptide of 36 amino acids 
residues. In blood plasma and urine, several forms of hBD-1 have been isolated ranging in 
length from 36 to 47 amino acids residues (Valore et al., 1998). Recombinant and natural 
 15
hBD-1 forms exhibit salt-sensitive antimicrobial activity against various laboratory and 
clinical strains of E. coli at micromolar concentrations (0.3-10µM). Moreover it was 
reported that concentrations of 1-10µg/ml of a recombinant baculovirus-derived hBD-1 
preparation killed P. aeruginosa. LD50 (lethal dose that achieves a colony-forming units 
reduction of 50%) of P. aeruginosa was found to be 1µg/ml and 100ng/ml for hBD-1 and 
hBD-2, respectively (Singh et al., 1998). As yet, no studies have reported activity of hBD-1 
against Gram-positive bacteria such as S. aureus (Harder and Schröder, 2005a). In 
contrast to hBD-2 and hBD-3, gene expression of hBD-1 in KCs is not markedly induced 
by pro-inflammatory cytokines like IL-1β, TNF-α, TNF-γ or by bacteria like P. aeruginosa 
(Harder et al., 2004). Natural hBD-1 protein has not yet been isolated from human skin. 
However using in situ hybridization, hBD-1 mRNA expression was detected in the 
suprabasal KCs, sweat ducts of human skin (Fulton et al., 1997) and sebaceous glands 
(Ali et al., 2001).  
HBD-2 is a small, cationic peptide of 43 amino acids which was originally isolated from 
lesional psoriatic scale extracts using an E. coli affinity column (Harder et al., 1997). 
Natural hBD-2 derived from psoriatic scale shows preferential antimicrobial activity against 
Gram-negative bacteria such as nonmucoid and mucoid strains of P. aeruginosa and E. 
coli  (LD90, 10 mg/ml), less activity against C. albicans (LD90, 25 mg/ml) and only 
bacteriostatic activity against S. aureus at 100 mg/ml (Harder et al., 1997). Activity of hBD-
2 depends on ion composition and is sensitive to the concentration of NaCl. The ability of 
hBD-2 to inhibit bacterial growth diminishes when salt concentration is increased from 20 
to 150 mM (Bals et al., 1998; Tomita et al., 2000), suggesting that hBD-2 is unable to kill 
bacteria in serum or at skin surface covered with evaporated sweat (Schröder and Harder, 
2006). Pro-inflammatory cytokines like IL-1α, IL-1β and TNF-α or stimuli like heat-killed 
bacteria such as P. aeruginosa have proven to be the most effective inducer of hBD-2 in 
KCs (Harder et al., 1997; Huh et al., 2002; Sorensen et al., 2003).  
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In normal skin, hBD-2 immunoreactivity is located to the uppermost layers of the 
epidermis and SC thus providing a first-line defense against invading microbes (Ali et al., 
2001). On a subcellular level, hBD-2 is stored in lamellar bodies of stimulated KCs of the 
spinous and granular layer of the epidermis, suggesting that hBD-2 is released with the 
lipidlike contents of lamellar bodies (Oren et al., 2003). In contrast to psoriatic skin, healthy 
skin extracts harbor only low amounts of hBD-2 peptide (Schröder and Harder, 1999). 
HBD-2 is also seen in the stratified epithelia of the oral cavity as well as in gingival cells 
(Dale and Krisanaprakornkit, 2001). 
HBD-3 is a 5-kDa nonhemolytic and salt-insensitive antimicrobial peptide which has 
been originally isolated from human psoriatic scales and was cloned from KCs (Garcia et 
al., 2001a; Harder et al., 2001). In contrast to hBD-2, hBD-3 is a broad-spectrum 
antimicrobial peptide. It is active against a number of human pathogens, including 
methicillin-resistant strains of S. aureus (MRSA) and vancomycin-resistant E. faecium 
(VRE). Furthermore, when in vitro activities of hBD-3 alone or combined with lysozyme, 
metronidazole, amoxicillin and chlorhexidine were investigated against several oral 
bacteria, hBD-3 showed bactericidal activity against all of the bacterial species tested 
(Maisetta et al., 2003). Ultrastructural analyses of hBD-3-treated S. aureus have revealed 
signs of perforation of the peripheral cell wall, with explosion-like liberation of the plasma 
membrane within 30 min and bacteriolysis (Harder et al., 2001). The morphological effects 
resemble those seen when S. aureus is treated with penicillin (Schröder and Harder, 
2006). When comparing the induction of hBD-2 and hBD-3 in KCs, IL-1β was found to be 
the strongest inducer of hBD-2, whereas IFN-γ, which does not induce hBD-2, is the most 
powerful hBD-3-inducing cytokine (Harder et al., 2004). HBD-3 is widely expressed in skin, 
placenta, tonsil, trachea, tongue, and other oral tissues (Dunsche et al., 2001; Garcia et 
al., 2001a; Harder et al., 2001). 
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HBD-4 was initially identified by screening the human genome database (Garcia et al., 
2001b). The expression of hBD-4 in KCs was slightly up-regulated by contact of P. 
aeruginosa but was strongly induced by phorbol-myristate-acetate (PMA) (Harder et al., 
2004). However, so far attempts have failed to isolate hBD-4 peptide from psoriatic scales 
as well as from healthy human skin-derived SC (Harder and Schröder, 2005a). 
 
1.2.6. S100A7c (psoriasin) 
S100 proteins comprise a multigene family of low molecular weight cationic proteins 
which are characterized by two calcium-binding EF-hand motifs (Donato, 2001). Some of 
these proteins are expressed within the epidermis and antimicrobial properties have been 
described for several members of this family (Buchau et al., 2007; Ganz and Lehrer, 1997; 
Gläser et al., 2005; Gottsch et al., 1999; Wolf et al., 2007).  
The human S100A7 was first identified as a protein up-regulated in inflamed psoriatic 
skin (Madsen et al., 1991). Genomic analysis revealed five copies of S100A7-like genes 
(S100A7a-S100A7e) within the human genome, but only duplicates a-c were predicted to 
be coding (Kulski et al., 2003). The S100A7a and S100A7c share the highest amino acid 
sequence similarity (93%). The hypothetically translated S100A7b sequence has the least 
similarity, with only 50% of the amino acid sequences common to S100A7c. The S100A7d 
and S100A7e appear to be fragmented and therefore non-coding (Kulski et al., 2003). 
Among these five duplications only S100A7c was recovered from skin-washing fluids and 
extracts of SC (Schröder and Harder, 2006).  
Biochemical analyses of E. coli-killing activity in extracts of a healthy person’s SC 
identified S100A7c as a principal E. coli-cidal antimicrobial protein in healthy skin SC 
extracts. A detailed biochemical analysis of healthy SC-derived S100A7c, revealed 
S100A7c to be heterogeneous with the 11.366-Da form as the predominant S100A7c form 
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in these extracts. In skin, S100A7c is expressed focally and released from KCs. Apart from 
KCs, sebocytes, the lipid-secreting cells of sebaceous glands, also showed 
immunoreactive S100A7c indicating that S100A7c is possibly also secreted together with 
lipids. From skin washings using buffer or acetone (to extract skin lipoids), S100A7c could 
be recovered from both aqueous and acetone extracts, indicating that the highly 
hydrophobic S100A7c is also stored in the lipid layer of healthy skin (Gläser et al., 2005).   
In vitro, S100A7c shows preferentially antimicrobial activity against E. coli, with a LD90 
near 0.5 µM whereas there is bactericidal activity for P. aeruginosa and S. aureus at much 
higher concentrations (LD90 >30 µM), S100A7c is far less bactericidal for the commensal 
S. epidermidis (Gläser et al., 2005). Antimicrobial activity of S100A7c has been observed 
at increased concentrations of salt, neutral and acidic pH which is seen on surfaces of 
healthy skin and upon conditions, when sweat is evaporating (Gläser et al., 2005). Using a 
neutralizing monoclonal antibody in vivo and in vitro confirmed that S100A7c is the 
principal E. coli-bactericidal component of healthy skin. Moreover, pre-treatment of healthy 
skin with neutralizing S100A7c antibodies also resulted in an increase of commensals, 
suggesting that a permanent S100A7c ‘film’ at skin surfaces might also contribute to 
growth control of the commensal flora (Gläser et al., 2005).  
Until now, the exact mechanism by which S100A7c kills E. coli is unknown. S100A7c is 
characterized by two calcium-binding EF-hand motifs and its antimicrobial activity against 
E. coli is sensitive towards treatment with Zn2+but not Ca2+, Mg2+, Fe2+ or Mn2+. This 
suggests that sequestration of Zn2+is the mechanism how S100A7c possibly kills E. coli 
(Gläser et al., 2005). Deprivation of Zn2+ultimately affects Zn2+dependent enzymes; Zn2+as 
well as Cu2+are essential transition metal ions for functional E. coli superoxide dismutase 
suggesting that these bacteria have a particular need to defend themselves against 
oxidative damage by endogenously generated reactive oxygen species (Benov et al., 
1995; Benov et al., 1997). 
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1.3. Chemotactic properties of skin-derived antimicrobial peptides 
The earliest clues that defensins might play a role in adaptive immunity were the 
observations that α-defensin-1 and α-defensin-2 are chemotactic for human monocytes 
and T cells (Chertov et al., 1996; Territo et al., 1989). In the case of hBD-1 and hBD-2, 
which attract memory T cells and immature dendritic cells, the chemoattractant activity 
might be due to defensin binding to the chemokine receptor CCR6, which is also shared by 
the C-C chemokine ligand 20 (CCL20) (Yang et al., 1999a). Thus, it appears that CCR6 
functions as a receptor for both the chemokine CCL20 and β-defensins. Although the 
physiological importance of this interaction has not yet been shown, the high 
concentrations of hBD-2 in inflamed skin make it probable that this defensin could 
compete effectively with the natural CCL20, despite the higher affinity of the latter for 
CCR6 (Yang et al., 1999a). Recent structural analysis of CCL20 indicated marked 
similarities to hBD-2 in the putative receptor-binding region of CCL20. This might be of 
high relevance in vivo, because hBD-2 represents one of the major antimicrobial peptide in 
psoriatic lesions (Harder and Schröder, 2005b).  
HBD-3 has been shown to be chemotactic for immature dendritic cells as well as 
monocytes, but since monocytes do not express CCR6, hBD-3 might use an additional 
chemotaxin receptor (Garcia et al., 2001a; Yang et al., 1999b). In addition, hBD-4 has 
been reported to attract monocytes by as yet unknown mechanism (Garcia et al., 2001b).  
Despite the functional overlap and sharing of receptors, chemokines and defensins 
have no apparent homology at the amino acid level, and their evolutionary relationship is 
unclear at present (Hughes, 1999). On the basis of usage of chemokine receptors and the 
tertiary structural similarities between defensins and chemokines, the defensins were 
considered to be ‘microchemokines’ which act on cells of the adaptive immune system 
(Hoover et al., 2002; Oppenheim et al., 2003). 
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Sharing a receptor with chemotactic factors is not unique to β-defensins, because 
another major human antimicrobial peptide LL-37, also uses a chemotactic receptor, 
formyl peptide receptor-like 1 (FPRL1), to mediate its chemotactic and Ca2+-mobilizing 
activities (De et al., 2000). In contrast to β-defensins, LL-37 is chemotactic for neutrophils, 
monocytes and T cells in the micromolar range, but not for dendritic cells (Yang et al., 
2001).  Besides its direct antimicrobial and chemotactic function, LL-37 also has multiple 
roles as a mediator of inflammation, influencing diverse processes such as cell 
proliferation and migration, immune modulation, wound healing, angiogenesis and the 
release of cytokines and histamine (Bals and Wilson, 2003). By promoting re-
epithelialisation of human skin wounds, LL-37 could play a role in repair of damaged tissue 
(Heilborn et al., 2003).  
S100A7c exhibits strong chemotactic activity on CD4+ T lymphocytes and neutrophils 
(Jinquan et al., 1996). A recent study defined RAGE (receptor for advanced glycation end 
products) as the S100A7c receptor (Wolf et al., 2008). Taken together the chemotactic 
capacities of antimicrobial peptides suggest that they play a role in recruiting T cells, 
immature dendritic cells and monocytes to sites of infection, thereby facilitating (as 
adjuvants) the initiation of adaptive antimicrobial immune response. 
 
1.4. Antimicrobial peptides and diseases 
The observation that antimicrobial peptides are expressed in the uppermost parts of 
the epidermis in skin suggests the existence of a ‘protective chemical shield’. These 
antimicrobial peptides function as effector molecules in skin infections and inflammations. 
It is therefore interesting to speculate that a defect in this protective system may lead to 
recurrent local infections, which in turn may lead to inflammation (Ong et al., 2002; 
Schröder and Harder, 2006). 
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On the other hand, it is possible that overexpression of antimicrobial peptides in skin 
may lead to increased protection. This hypothesis is supported by a disease concomitance 
seen in patients with psoriasis, a non-infective inflammatory skin disease, which 
unexpectedly rarely suffer from infectious skin diseases (Henseler and Christophers, 
1995). Biochemical analysis of psoriatic scale extracts revealed the presence of hBD-2, 
RNase 7 and S100A7c as principal antimicrobial peptides in these extracts (Schröder and 
Harder, 2006). Atopic dermatitis, is a chronic inflammatory skin disease associated with 
significant barrier disruption, T-helper type 2 mediated skin inflammation, and an impaired 
innate immune response. These characteristics increase the susceptibility of atopic 
dermatitis patients to recurrent skin infections. In contrast to psoriasis, patients with atopic 
dermatitis often suffer from skin infections with S. aureus and a decreased expression of 
hBD-2, hBD-3 and LL-37 has been observed in acute and chronic lesions of these patients 
(Ong et al., 2002). However a recent study demonstrated an increase of S100A7c protein 
in paitents with atopic dermatitis (Gläser et al., 2008). 
The involvement of antimicrobial peptides is not only restricted to skin disorders. Cystic 
fibrosis (CF) is a common autosomal recessive genetic disease caused by mutations in 
the cystic fibrosis transmembrane regulator (CFTR) gene. The CFTR gene encodes a 
regulated chloride channel that also functions as a regulator of other ion channels. The 
main cause of morbidity and mortality in CF is respiratory failure due to progressive 
destruction of the airways and lungs by recurrent infections and inflammation. These 
events indicate a local defect in epithelial host defense, as the infection almost always 
remains localized in the lung and does not spread elsewhere or affect non-respiratory 
epithelia. It is proposed that the local host defense impairment is, at least in these paitents, 
due to the inhibition of defensin activity by the abnormal ionic environment of airway fluid. 
Cl− concentrations of airway fluid is increased from 80 mM of healthy individuals to 170 
mM in patients with CF, respectively (Smith et al., 1996). Indeed, activity of hBD-2 
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depends on ion composition and is sensitive to the concentration of NaCl. The ability of 
hBD-2 to inhibit bacterial growth diminishes when salt concentration is increased from 20 
to 150 mM (Bals et al., 1998; Harder et al., 2000).   
 
1.5. Recognition of microbial components  
The innate immune system is the first line of the defense that protects hosts from 
invading microbial pathogens. It recognizes microorganisms by specific microbial 
components designated as pathogen-associated molecular patterns (PAMPs). These 
PAMPs, ranging from lipids, lipoproteins, proteins and nucleic acids are produced by 
microorganisms but not by the host.  PAMPs are essential for the survival of the 
microorganism and therefore difficult for the microorganism to alter or to substitute. For 
instance, lipopolysaccaride (LPS) is a well defined PAMP of Gram-negative bacteria; 
Gram-positive bacteria, by contrast, produce lipoteichoic acid (LTA) and lipoproteins which 
are recognized as PAMPs. Peptidoglycan is a PAMP of the cell wall and is produced by 
Gram-positive as well as Gram-negative bacteria. Flagellin, another important PAMP, is 
the major protein constituent of bacterial flagella. Single- and double-stranded RNA 
(ssRNA, dsRNA) make up PAMPs of viruses and β-glucan is an important PAMP of fungi 
(Ishii et al., 2008). 
Host cells express various pattern recognition receptors (PRRs) which are able to 
sense diverse PAMPs (Akira and Hemmi, 2003). Recognition of PAMPs by PRRs 
activates intracellular signaling pathways that culminate in the induction of antimicrobial 
peptides, inflammatory cytokines, chemokines, interferons and up-regulation of co-
stimulatory molecules (Ishii et al., 2008). Among the major PRRs are the Toll-like 
receptors (TLRs) which recognize pathogens at either the cell surface or 
lysosome/endosome membranes (Ishii et al., 2008) and the nucleotide-binding 
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oligomerization domain (NOD)-like receptors (NLRs) which recognize pathogens that have 
invaded the cytosol (Kanneganti et al., 2007).  
TLRs: The discovery of the TLR family began with the identification of Toll receptor of 
drosophila and which was found to be essential for establishing dorsoventral polarity 
during embryogenesis in drosophila (Hashimoto et al., 1988). Subsequent studies 
revealed that Toll also has an essential role in the insect innate immune response against 
fungal infection (Lemaitre et al., 1996). After the discovery of Toll in drosophila, a number 
of structurally related proteins were identified in mammals and were thus named “Toll-like” 
receptors. To date, 11 human TLRs and 13 mouse TLRs have been identified, and each 
TLR appears to recognize distinct PAMPs derived from various microorganisms, including 
bacteria, viruses, protozoa and fungi (listed in Table 1) (Akira et al., 2006). The TLRs are 
type I integral membrane glycoproteins, and on the basis of considerable homology in the 
cytoplasmic region of the IL-1 receptor, known as the TIR domain, which is required for 
downstream signaling, they are members of a larger superfamily that includes the 
interleukin-1 receptors (IL-1Rs). By contrast, the extracellular region of the TLRs and IL-
1Rs differs markedly; the extracellular region of TLRs contains leucine-rich repeat (LRR) 
motifs which are responsible for recognition of PAMPs, whereas the extracellular region of 
IL-1Rs contains three immunoglobulin-like domains. The LRR domains are composed of 
19–25 tandem LRR motifs, each of which is 24–29 amino acids in length (Akira et al., 
2006). 
TLRs can be further divided into several subfamilies, each of which recognizes related 
PAMPs: the subfamily of TLR1, TLR2, and TLR6 recognizes lipids, whereas the highly 
related TLR7, TLR8, and TLR9 recognize nucleic acids (Akira and Takeda, 2004).  
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Table 1. TLR Recognition of Microbial Components 
Microbial Components Species TLR Usage 
Bacteria   
Lipopolysaccharide (LPS) Gram-negative bacteria TLR4 
Diacyl lipopeptides Mycoplasma TLR6/TLR2 
Triacyl lipopeptides Bacteria and mycobacteria TLR1/TLR2 
Lipoteichoic acids (LTA) Group B Streptococcus TLR6/TLR2 
Peptidoglycan (PG) Gram-positive bacteria TLR2 
Lipoarabinomannan Mycobacteria TLR2 
Flagellin Flagellated bacteria TLR5 
CpG-DNA Bacteria and mycobacteria TLR9 
not determined Uropathogenic bacteria TLR11 
Fungus   
Zymosan Saccharomyces cerevisiae TLR6/TLR2 
Phospholipomannan Candida albicans TLR2 
Mannan Candida albicans TLR4 
Glucuronoxylomannan Cryptococcus neoformans TLR2 and TLR4 
Parasites   
Glycoinositolphospholipids Trypanosoma TLR4 
Hemozoin Plasmodium TLR9 
Profilin-like molecule Toxoplasma gondii TLR11 
Viruses   
DNA Viruses TLR9 
double stranded RNA Viruses TLR3 
single stranded RNA RNA viruses TLR7 and TLR8 
 
 
 
TLRs are expressed on various immune system cells, including macrophages, 
dendritic cells, B cells, specific types of T cells, but also in cells which are not part of the 
immune system such as fibroblasts and epithelial cells (Kadowaki et al., 2001; Köllisch et 
al., 2005; Lebre et al., 2007; Miller et al., 2005; Miller and Modlin, 2007) . TLRs may be 
expressed extra- or intracellularly. TLRs 1, 2, 4, 5, and 6 are expressed on the cell 
surface, while TLRs 3, 7, 8, and 9 are found almost exclusively in intracellular 
compartments such as endosomes, and their ligands, mainly nucleic acids, require 
internalization to the endosome before signaling is possible. Some TLR may function as 
heterodimers. For example, TLR1 and TLR6 serve as co-receptors to TLR2, and TLR2/1 
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and TLR2/6 heterodimers recognize bacterial tri-acyl lipopeptides and di-acyl lipopeptides, 
respectively (Ishii et al., 2008).  
In human KCs, functional expression of TLRs1, 2, 3, 5 and 9 has been demonstrated 
(Köllisch et al., 2005; Lebre et al., 2007; Miller et al., 2005), while expression of TLR4 was 
detected by some but not other authors (Baker et al., 2003; Kawai, 2003; Köllisch et al., 
2005). In studies where KCs were derived form plastic surgery skin specimens functional 
TLR4 activity was detected (Buchau et al., 2007; Lebre et al., 2007; Pivarcsi et al., 2003) 
whereas in KCs derived from human foreskin specimens none such activity was seen 
(Köllisch et al., 2005; Mempel et al., 2003). It has been suggested that these controversial 
reports may be to different culture conditions or origin of KCs (Buchau et al., 2007).   
NLRs: NLRs are a large family of cytoplasmic PRRs which are implicated in the 
recognition of bacterial components. Proteins of this family, like those of the TLR family, 
possess LRRs that mediates ligand sensing (Kanneganti et al., 2007). For instance, NOD1 
and NOD2, members of the NLRs family, detect γ-D-glutamyl-meso-diaminopimelic acid 
(iE-DAP) and muramyl dipeptide (MDP), found on bacterial peptidoglycan, respectively. 
Lack of either NOD1 or NOD2 in macrophages abolished proinflammatory cytokine 
production in response to the corresponding ligands (Kobayashi et al., 2005). Expression 
of NOD2 was detected in primary KCs, and stimulation with MDP induced hBD-2 peptide 
release (Voss et al., 2006). 
 
1.5.1. TLRs in distinguished skin diseases and infections 
Psoriasis: Psoriasis is an inflammatory skin disease that is characterized clinically by 
cutaneous erythematous plaques covered with a silvery scale. Histologic evaluation of 
psoriatic plaques reveal a thickened epidermis, with KC hyperproliferation and an 
inflammatory infiltrate in the dermis comprised of T cells, macrophages, and dendritic cells 
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(Kupper and Fuhlbrigge, 2004). There are a number of reports that evaluated the 
expression of TLRs by KCs in psoriasis. One study demonstrated that TLR1 was 
expressed by KCs in normal skin and in psoriasis. They further demonstrated that there 
was an enhanced TLR1 expression in the basal layer of KCs in psoriatic plaques 
compared with normal skin (Curry et al., 2003). Another study demonstrated that KCs of 
psoriasis lesions had a higher expression of TLR2 and less expression of TLR5 than 
normal skin (Baker et al., 2003). A study by Miller et al. found that TLR5 and TLR9 
expression in psoriasis lesion are higher compared to normal skin (Miller et al., 2005). The 
role and function of TLRs expression by KCs in psoriasis lesions is unknown, but 
superinfection of lesions of stable plaque psoriasis by bacteria occurs only rarely. This 
decreased susceptibility to infection may be because of increased levels of antimicrobial 
peptides such as β-defensins, cathelicidin and S100A7c in psoriatic skin (Harder and 
Schröder, 2005b). 
Acne vulgaris: Acne vulgaris is an inflammatory skin disease that mainly occurs 
during adolescence and involves inflammation of the pilosebaceous unit. Although the 
pathogenesis of acne vulgaris is multifactorial, one of the factors that contribute to acne 
lesions is inflammation caused by the anaerobic bacterium Propionibacterium acnes 
(Miller and Modlin, 2007). It has been demonstrated that the activation of TLR2 by P. 
acnes in vitro induced IL-12 and IL-18 production by primary human monocytes (Kim et al., 
2002). Another study demonstrated that all-trans retinoic acid, which is used as a topical 
treatment for acne, down-regulated the expression and activation of TLR2 on cultured 
monocytes (Liu et al., 2005). Moreover, it has been demonstrated that P. acnes induce 
hDB-2 and IL-8 in human KCs and this induction is inhibited by anti-TLR2 and anti-TLR4 
neutralizing antibodies (Nagy et al., 2005). Taken together these studies indicate the 
importance of TLRs in the pathogenesis of acne vulgaris.  
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Atopic dermatitis: Atopic dermatitis is a chronic inflammatory skin disease associated 
with significant barrier disruption, T-helper type 2 mediated skin inflammation, and an 
impaired innate immune response. These characteristics increase the susceptibility of 
atopic dermatitis patients to recurrent skin infections (Ong et al., 2002). A study 
demonstrated that a polymorphism in TLR2 correlates with a severe phenotype of atopic 
dermatitis. This study suggests that lack of functional TLR2 may exacerbate atopic 
dermatitis (Ahmad-Nejad et al., 2004). Although, the activation of TLR2 in KCs induce the 
expression of hBD-2 (Kawai, 2003), but a direct role of TLR2 in the pathogenesis of atopic 
dermatitis is still unclear.  
S. aureus skin infections: S. aureus is a Gram-positive extracellular bacterium that is 
responsible for the vast majority of skin and soft tissue infections in humans, including 
impetigo, folliculitis, and cellulitis. Several in vitro experiments have demonstrated that 
lipoteichoic acid of S. aureus activate immune cells via TLR2 (Schröder et al., 2003; 
Takeuchi et al., 1999). In addition, in vivo studies of TLR2-deficient mice have 
demonstrated that these mice are more susceptible to S. aureus skin infection and 
develop larger skin lesions than wild-type mice (Miller et al., 2006).These data provide 
evidence that TLR2 is important in host defense against S. aureus infections in the skin. 
Candidiasis: Candidiasis is an infection caused by the yeast C. albicans which is a 
dimorphic fungal pathogen. Clinical infections include mucocutaneous infections as well as 
invasive and life-threatening infections usually seen in immunocompromised patients 
(Levitz, 1998). In vitro studies have shown that C. albicans -derived mannan induces in 
human monocytes the production of TNF-α  in a TLR4-dependent manner (Tada et al., 
2002). In an in vitro model it has been demonstrated that treatment of KCs with C. albicans 
and mannan resulted in the activation and nuclear translocation of NF-κB. In addition, it 
was shown that Candida-killing activity of KCs was NF-κB-dependent and that this activity 
could be inhibited by anti-TLR2 and anti-TLR4 neutralizing antibodies (Pivarcsi et al., 
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2003). These studies may suggest an important role of TLRs in C. albicans skin infections. 
The clinical relevance of these in vitro studies are still unclear because no published report 
of in vivo C. albicans skin infections in context with TLR2 or TLR4 have been found (Miller 
and Modlin, 2007).  
Herpes simplex virus: Herpes simplex virus (HSV) and Varicella-Zoster virus (VZV) 
are common viral pathogens that infect human skin. It has been demonstrated that VZV 
activates induced IL-6 cytokine response of human monocytes in a TLR2-dependent 
manner (Wang et al., 2005). HSV is recognized through both TLR2 and TLR9 in dendritic 
cells for the induction of IL-6 and IL-12 secretion (Sato et al., 2006). Thus, suggesting for 
TLR2 and TLR9 an important role in recognition and host defense against HSV and VZV 
infections in the skin 
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2. Objectives and format of the dissertation 
Human skin is an effective barrier against invading microorganisms. This protective 
function is partly mediated by the presence of antimicrobial peptides. The overall objective 
of this dissertation was to identify molecular mechanisms by which antimicrobial peptides 
of human skin are regulated. The aim of the first part was to determine the mechanism by 
which E. coli induces the up-regulation of the antimicrobial peptide S100A7c, the principal 
E. coli–cidal factor present at the surface of human epidermis (Gläser et al., 2005). The 
objective of the second part was to investigate the potential role of RNase-RI interaction in 
human skin and its implication on the RNase-dependent antimicrobial defense system. 
The following part of the dissertation is organized in two chapters:  
Chapter I has been published in the “Federation of American Societies for Experimental 
Biology”. Abtin, A., Eckhart, L., Mildner, M., Gruber, F., Schröder, J. M., Tschachler, E. 
(2008). Flagellin is the principal inducer of the antimicrobial peptide S100A7c 
(psoriasin) in human epidermal keratinocytes exposed to Escherichia coli. FASEB J.  
22: 2168-2176 
Chapter II has been accepted for publication in the “Journal of Investigative Dermatology”. 
Abtin, A., Eckhart, L., Mildner, M., Ghannadan, M., Harder, J., Schröder, J. M., Tschachler, 
E. (2009). Degradation by stratum corneum proteases prevents endogenous RNase 
inhibitor from blocking antimicrobial activities of RNase 5 and RNase 7. 
  
Both chapters contain the following sections: Title, Abstract, Introduction, Materials and 
Methods, Results, Discussion, Figures and References. 
References cited in the Introduction, Objectives and Discussion are listed at the end of 
the dissertation.  
 30
3. Chapter I: Flagellin is the principal inducer of the 
antimicrobial peptide S100A7c (psoriasin) in human epidermal 
keratinocytes exposed to Escherichia coli. 
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ABSTRACT Epidermal keratinocytes (KCs) express
antimicrobial peptides as a part of the innate immune
response. It has recently been shown that the culture
supernatant of Escherichia coli induces the expression
of S100A7c (psoriasin) in KCs and that S100A7c effi-
ciently kills E. coli. Here we have investigated which of
the microbial components triggers the up-regulation of
S100A7c expression. Exposure of human primary KCs
to ligands of the human Toll-like receptors (TLRs)
revealed that only the TLR5 ligand flagellin strongly
induced the expression of S100A7c mRNA and protein,
whereas all other TLR ligands had no significant effect.
In contrast to the supernatant from flagellated wild-type
(WT) E. coli, the supernatant of a flagellin-deficient E.
coli strain (FliC) did not induce S100A7c expression.
Small interfering RNA-mediated knockdown of TLR5
expression suppressed the ability of KCs to up-regulate
S100A7c expression in response to both flagellin and
WT E. coli supernatant. Taken together, our data dem-
onstrate that bacterial flagellin is essential and suffi-
cient for the induction of S100A7c expression in KCs
by E. coli.—Abtin, A., Eckhart, L., Mildner, M., Gruber,
F., Schro¨der, J.-M., Tschachler, E. Flagellin is the
principal inducer of the antimicrobial peptide S100A7c
(psoriasin) in human epidermal keratinocytes exposed
to Escherichia coli. FASEB J. 22, 2168–2176 (2008)
Key Words: innate immunity  Toll-like receptor  TLR  patho-
gen-associated molecular pattern  PAMP  antimicrobial de-
fense
Human skin is an effective barrier against invading
microorganisms. This protective function is partly me-
diated by the presence of antimicrobial peptides
(AMPs) in the skin (1, 2). Although known for a long
time in other species (3, 4) and in other organ systems
of humans (5, 6), the presence and importance of
AMPs in human skin has only recently been demon-
strated (1, 7). AMPs of the skin comprise a heteroge-
neous group of molecules, such as human -defensin
(hBD) -1, hBD-2, hBD-3, RNase 7, cathelicidin, and
S100A7c (2). The antimicrobial activity described for
AMPs is due to perforation and disruption of the
bacterial membrane (e.g., hBD-2, RNase 7, and catheli-
cidin) (8–10) by deprivation of essential trace elements
(e.g., S100A7c) (1) or by as yet unknown mechanisms
(e.g., hBD-1 and hBD-3) (2). Studies using mouse
models with deficiencies in AMP genes have empha-
sized the importance of some of these peptides in the
defense against invasive bacterial infections in epithelia
of different organs (11–13). For example, mice defi-
cient in the expression of CRAMP (the mouse homolog
to the human cathelicidin) were more susceptible to
skin infections caused by group A Streptococcus (12) and
urinary tract infections by Escherichia coli (11).
One arm of the antimicrobial defense of the skin is
provided by members of the multifunctional S100
protein family. S100 proteins have a molecular mass of
9–13 kDa and are characterized by two calcium-binding
EF-hand motifs (14). Eleven proteins of the S100A
family, i.e., S100A2, S100A3, S100A4, S100A6, S100A7c,
S100A8, S100A9, S100A10, S100A11, S100A12, and
S100A15, are expressed in the epidermis (15–17).
S100A7c, S100A12, and S100A15 have Gram-negative
bacteria-killing activities (1, 18, 19), and a heterodimer
complex of S100A8/S100A9 suppresses the growth of
the yeast Candida albicans (20). S100A7c has been
identified as a protein that is up-regulated in lesional
psoriatic skin; hence, it was initially named psoriasin
(21). However, in the meantime it has been established
that S100A7c is also expressed in normal skin (1, 21).
S100A7c is encoded by a gene located on chromosome
1q21 within a cluster of five S100A7-like genes, S100A7a
through S100A7e. S100A7a–S100A7c transcripts encode
functional proteins whereas S100A7d and S100A7e are
pseudogenes (22). S100A7c shows 93 and 50% amino
acid sequence similarity compared with S100A7a and
S100A7b, respectively (22). A recent report has pro-
vided evidence that the human S100A7 genes have
arisen by repeated duplications of an ancient S100A7
gene whereas the mouse has lost the S100A7 gene (23).
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Of all the proteins of the S100A7 family only S100A7c is
present at high concentrations in human stratum cor-
neum (2). Gla¨ser et al. (1) have shown that E. coli is
effectively killed on human skin and that this killing
activity was inhibited in vivo by a neutralizing antibody
to S100A7c. Furthermore, this report demonstrated
that S100A7c is up-regulated by exposing keratinocytes
(KCs) to E. coli culture supernatants. Together, these
data suggest that S100A7c has a critical role in the skin
defense against E. coli and probably also against related
bacteria.
The induction of antimicrobial molecules is a central
mechanism of the innate immune defense. Compo-
nents of different pathogens, i.e., pathogen-associated
molecular patterns (PAMPs) are recognized by pattern
recognition receptors, such as the Toll-like receptors
(TLRs) (24), which are expressed on a wide variety of
immune and nonimmune cells (25–29). To date, 10
members of the TLR family of genes have been identi-
fied in humans (30, 31). Each TLR recognizes distinct
PAMPs derived from various microorganisms. For in-
stance, TLR3 recognizes viral double-stranded RNA
(32), TLR4 recognizes lipopolysaccharide (LPS) (33),
and TLR5 recognizes bacterial flagellin (34). Engage-
ment of TLRs by microbial components initiates signal-
ing cascades that activate mitogen-activated protein
kinases and induces nuclear translocation of NF-B
(35), which consequently leads to the production of
proinflammatory cytokines (35) and the induction of
AMPs (such as hBD-2) in various epithelial cells (28,
36–38). In human KCs, functional expression of TLR1,
2, 3, 5, and 9 has been demonstrated (26–28), whereas
expression of TLR4 in KCs was detected by some but
not other authors (27, 39, 40). TLR2 has been shown to
mediate the activation of NF-B gene expression in
response to Staphylococcus aureus (41). The bacterial
components by which E. coli induces the expression of
S100A7c have not yet been identified.
Here we have investigated whether TLR ligands are
able to up-regulate S100A7c expression in KCs and
whether any of these ligands are involved in the induc-
tion of S100A7c by E. coli culture supernatants. The
regulation of S100A7c was compared with that of the
antimicrobial peptide hBD-2. Our results reveal that
the induction by E. coli of both S100A7c and hBD-2
depends on the presence of bacterial flagellin and
TLR5 on KCs.
MATERIALS AND METHODS
Cell culture
Human primary KCs prepared from neonatal foreskin were
obtained from Clonetics (San Diego, CA, USA) and cultured
in serum-free keratinocyte growth medium (KGM; Clonetics)
as described previously (42). For stimulation, third passage
KCs were cultured in 12-well tissue culture plates (Corning
Incorporated, Corning, NY, USA) and used at a confluence of
60–70%. Stimulation was performed in keratinocyte basal
medium (KBM; Clonetics).
Reagents used for treatment of KCs
For in vitro assays, recombinant interleukin-1 (IL-1; R&D
Systems, Minneapolis, MN, USA), IL-8 (R&D Systems), and
the following TLR ligands (InvivoGen, San Diego, CA, USA)
were used: synthetic tripalmitoylated lipopeptide (Pam3CSK4;
TLR1/2 ligand), heat-killed Listeria monocytogenes (HKLM; TLR2
ligand), poly(I:C), a synthetic analog of double-stranded RNA
(TLR3 ligand), ultrapure LPS from E. coli K12 (TLR4 ligand),
purified flagellin from Salmonella typhimurium (TLR5 ligand),
synthetic lipoprotein of Mycoplasma salivarium (FSL1; TLR6/2
ligand), imiquimod (R837; TLR7 ligand), single-stranded
RNA40 (TLR8 ligand), and ODN2006 (CpG oligonucleotide
type B; TLR9 ligand). For IL-1 neutralizing experiments, KCs
were used at a confluence of 60–70% in 12-well tissue culture
plates. Before stimulation with IL-1 and flagellin, cells were
preincubated for 90 min with a polyclonal goat IgG IL-1
neutralizing antibody (2 g/ml; R&D Systems) or a polyclonal
goat IgG isotype control (2 g/ml; Santa Cruz Biotechnology,
Santa Cruz, CA, USA). For blocking IL-1 receptors, cells were
incubated for 90 min with 100 ng/ml IL-1 receptor antagonist
(IL-1Ra; Strathmann Biotec, Hamburg, Germany) before stim-
ulation with flagellin or IL-1.
RNA isolation and quantitative real-time polymerase chain
reaction (PCR)
After stimulation, cells were washed with PBS, and RNA was
isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. For cDNA synthe-
sis RNA was reverse-transcribed with murine leukemia virus-
reverse transcriptase using the Gene Amp RNA PCR kit (Ap-
plied Biosystems, Foster City, CA, USA) and oligo(dT) primers
(Roche Diagnostics, Basel, Switzerland). cDNA sequences of the
genes under investigation were obtained from GenBank. Prim-
ers were designed using PRIMER3 software from the Whitehead
Institute for Biomedical Research (Cambridge, MA, USA). The
following forward (F) and reverse (R) intron-spanning primers
were used—for -2-microglobulin: F, 5-GATGAGTATGC-
CTGCCGTGTG-3; R, 5-CAATCCAAATGCGGCATCT-3;
for S100A7c: F, 5-GGAGAACTTCCCCAACTTCCTT-3; R,
5-GGAGAAGACATTTTATTGTTCCT-3; for S100A7a: F,
5-AAATACACCGGACGTGATGG-3; R, 5-TCTTGTCCTT-
TTTCTCAAAGACAGT-3; for S100A7b: F, 5-GATGAATATCC-
CTCTAGGTGAGAAAGT-3; R, 5-GGTGCCACTCCATGCAT-
TAT-3; for hBD-2: F, 5-ATCAGCCATGAGGGTCTTGT-3; R,
5 -GAGACCACAGGTGCCATTTT-3 ; for hBD-1: F,
5-CCCAGTTCCTGAAATCCTGA-3; R, 5-CTTCTGGT-
CACTCCCAGCTC-3; for hBD-3: F, 5-AGCTGTGGCTG-
GAACCTTTA-3; R, 5-CGATCTGTTCCTCCTTTGGA-3; for
cathelicidin: F, 5-GCTAACCTCTACCGCCTCCT-3; R,
5 -GGTCACTGTCCCCATACACC-3 ; for TLR5: F,
5-CTAGAAGTCCCTTCTGCTAGGAC-3; R, 5-AAGGGG-
AAGGATGAAGCAGT-3; and for IL-8: F, 5-CTCTTGGCA-
GCCTTCCTGATT-3; R, 5-TATGCACTGACATCTAAGTT-
CTTTAGCA-3. Quantitative real-time PCR was performed
by LightCycler technology using the Fast Start SYBR Green
I Kit for amplification and detection (Roche Diagnostics)
as described previously (43). Determination of relative
quantification of target gene expression and amplification
efficiencies was performed using a mathematical model by
Pfaffl (44). The expression of the target gene was normal-
ized to the expression of -2-microglobulin. All real-time
PCRs were performed in triplicate. The specificity of the
reactions was confirmed by sequencing of the PCR prod-
ucts.
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Bacterial strains and KC stimulation
E. coli NK 9373 and E. coli NK 9375 (FliC; a flagellin-deficient
strain having an in-frame deletion within the fliC gene) (45)
were kindly provided by Dr. David Bates (Harvard University,
Cambridge, MA, USA). Bacterial culture supernatants were
prepared as described previously (1) with minor modifica-
tions. Briefly bacteria were grown in tryptic soy broth (TSB)
(Fluka, Buchs, Switzerland) with agitation at 37°C until an
optical density of 1.0 (OD600) was reached. Then 1 ml of this
culture was combined with 9 ml of TSB and incubated
overnight in 75-cm2 flasks (Cellstar, Frickenhausen, Ger-
many) at 37°C without agitation. Optical density (OD600) of
overnight cultures of E. coli strains was set with TSB to 1.7.
Subsequently, bacteria were heat-killed in a water bath at
65°C for 60 min. Heat-killing was verified by a plating culture
on Luria-Bertani agar. After heat-killing, cultures were centri-
fuged at 5000 g for 15 min. The resulting supernatants were
diluted 1:100 in KBM and used to stimulate KCs from which
the previous medium had been removed.
Cytokine measurement
Culture supernatants of stimulated KCs were depleted by
centrifugation of detached cells or cell fragments and stored
at 20°C until analysis. Concentrations of IL-1 and IL-8
were determined by ELISA (R&D Systems) according to the
manufacturer’s instructions.
Small interfering (si) RNA transfections
Third-passage primary KCs were used at a confluence of
60–70% in 12-well tissue culture plates. KCs were transfected
with the following Stealth siRNAs using Lipofectamine 2000
reagent (Invitrogen): TLR5-siRNA1, 5-CAUCCUUCAU-
UUGGGAAGUUGAAUU-3; TLR5-siRNA2, 5-CCACCAG-
GAGUAUUUAGCCAUCUGA-3; control siRNA1 (scrambled
sequence of TLR5-siRNA1), 5-CAUACUUGUUUAAGGGUU-
GACCAUU-3; and control siRNA2 (scrambled sequence of
TLR5-siRNA2), 5-CCAGGAUGAUUAGAUACCCUCCUGA-3.
Lipofectamine 2000 (30 l) was mixed with 60 l of a 20 M
siRNA solution (1:1 mix of siRNA1 and -2) and 4 ml of
OPTI-MEM medium (Gibco BRL, Gaithersburg, MD, USA).
After 30 min at room temperature, 4 ml of KBM was added, and
the solution was poured onto the KCs in 12-well tissue culture
plates (600 l/well) for 24 h. Afterward the medium was
changed to KGM, and cells were left for another 24 h before
stimulation.
Western blot analysis
For analysis of protein expression, KCs were lysed in SDS-
PAGE loading buffer (50 mM Tris, pH 7.4, 2% SDS). After
sonication, insoluble cell debris was removed by centrifuga-
tion, and protein concentration was measured by the bicin-
choninic acid method (Pierce Biotechnology, Rockford, IL,
USA). Western blot analysis was performed as described
previously (46). The following first step antibodies were used:
mouse monoclonal IgG1 anti-S100A7c clone 47C1068 (di-
lution 1:500; Abcam, Cambridge, UK) and mouse mono-
clonal IgG2b anti-glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (dilution 1:400; Biogenesis, Poole, UK).
The membranes were developed using the Chemiglow
reagent (Alphainnotech, San Leandro, CA, USA) accord-
ing to the manufacturer’s instructions.
RESULTS
Flagellin but not other TLR ligands induces S100A7c
expression in human primary KCs
To investigate the role of TLRs in the regulation of
S100A7c expression in KCs, primary human epidermal
KCs were stimulated with ligands for TLR1 through
TLR9. The expression of S100A7c and other AMPs was
determined by quantitative real-time PCR analysis.
S100A7c mRNA was up-regulated by the TLR5 ligand
flagellin but not by other TLR ligands (Fig. 1A). The
level of up-regulation of S100A7c induced by flagellin
equalled that induced by IL-1 (Fig. 1A). Among the
other AMPs investigated, hBD-1, hBD-3, RNase7, and
cathelicidin were not changed by stimulation with TLR
ligands (data not shown). hBD-2 was up-regulated by
flagellin, poly(I:C) (TLR3 ligand), and ODN2006
(TLR9 ligand) in a manner comparable with the results
of previous studies (28, 36) (Fig. 1B). Similar to the
results obtained with S100A7c, hBD-2 mRNA was al-
most as strongly induced by flagellin as by IL-1.
Because hBD-2 expression showed responsiveness to
flagellin similar to that of S100A7c, it was used for
comparison in all further experiments.
Flagellin induces S100A7c expression in an
IL-1-independent manner
Next we determined the dose and time dependence of
flagellin-induced AMP expression. S100A7c mRNA was
significantly induced at a flagellin concentration of 5
ng/ml (Fig. 2A), whereas 1 ng/ml flagellin sufficed to
up-regulate hBD-2 mRNA expression (Fig. 2B). Increas-
ing concentrations of flagellin up to 10 ng/ml in-
duced higher expression levels of both S100A7c and
hBD-2 mRNA, whereas further elevation of the flagel-
lin did not cause significant additional up-regulation
(Fig. 2A, B) and even reduced the inductive effect of
flagellin (Fig. 2B). The maximum up-regulation of both
S100A7c and hBD-2 mRNA was observed at time points
later than 8 h after addition of flagellin to the KC
culture medium (Fig. 2C, D). Essentially the same
temporal expression pattern was induced by stimula-
tion with IL-1 (Fig. 2C, D), whereas IL-8 mRNA was
up-regulated as early as 2 h after stimulation and
decreased later (Fig. 2E).
The time course of S100A7c or hBD-2 expression
seemed to be compatible with an indirect mechanism
of regulation involving flagellin-induced cytokine re-
lease and subsequent induction of S100A7c and hBD-2
by cytokines. We therefore investigated the role of two
candidate cytokines, i.e., IL-1 and IL-8.
Because IL-1 is stored in KCs and can be released by
various stress stimuli (47), we determined by ELISA the
IL-1 concentration in KC culture supernatant at 2 h
after flagellin stimulation, a time point before the
increase of S100A7c and hBD-2 expression (Fig. 2C, D).
However, IL-1 concentrations did not differ between
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supernatants of flagellin-stimulated and unstimulated
KCs either at 2 h or 24 h after stimulation (Fig. 3A).
To exclude the theoretical possibility that released
IL-1 is captured by cellular receptors and exerts its
effects without increasing in concentration in the bulk
supernatant, KCs were preincubated with an IL-1
neutralizing antibody or its corresponding isotype con-
trol, and/or with an IL-1Ra that neutralizes both IL-1
and IL-1. Neither treatment interfered with S100A7c
or hBD-2 induction by flagellin (Fig. 3B, C), demon-
strating that extracellular IL-1 is not required for the
observed effects of flagellin. Consistent with previous
reports (48, 49), addition of IL-8 did not alter the
mRNA expression levels of S100A7c and hBD-2 (Fig. 2F).
Flagellin-deficient E. coli does not induce S100A7c
expression
To determine the contribution of flagellin in the
induction of S100A7c expression by E. coli culture
supernatant, we compared a wild-type (WT) flagellated
E. coli strain (NK 9373) and a flagellin-deficient (FliC)
E. coli strain (NK 9375) with regard to their capacity to
induce S100A7c expression. Culture supernatants of E.
coli strains were diluted 1:100 in KBM and applied to
KC cultures for 16 and 48 h. Quantitative real-time PCR
revealed that WT E. coli induced S100A7c and hBD-2
mRNA expression, whereas FliC E. coli did not (Fig.
4A, B). Neither WT nor FliC E. coli strains were able to
induce the expression of hBD-1, hBD-3, RNase7, and
cathelicidin (Supplemental Fig. 1). Western blot anal-
ysis of cell lysates showed that the increase of S100A7c
mRNA in response to flagellin or WT E. coli also
resulted in a strong increase of S100A7c protein (Fig.
4C). In contrast, FliC E. coli lacked the ability to
induce S100A7c protein production (Fig. 4C). Addition
of flagellin (10 ng/ml) to the FliC E. coli culture
supernatant restored the induction of S100A7c protein
expression (Fig. 4C), demonstrating that the failure of
this strain to induce S100A7c is not due to the presence
of an inhibitor. Notably, supernatants of FliC E. coli
were also able to induce secretion of IL-8 by KCs,
although less than WT E. coli (Fig. 4D). These findings
demonstrate that flagellin is essential for E. coli-mediated
induction of S100A7c and hBD-2 but only partially con-
tributes to E. coli-mediated cytokine secretion from KCs.
Because it has been reported that S100A7a, mislead-
ingly named human S100A15 (50), is also up-regulated
by E. coli (18), we compared the potential biological
significance of S100A7a and S100A7c in the defense
against E. coli. Like S100A7c, S100A7a was up-regulated
by IL-1, flagellin, and WT E. coli but not by FliC E. coli
(Supplemental Fig. 2A). In contrast with the conclu-
sions of another report (18), we did not observe an
increase in S100A7a in response to the TLR4 ligand
LPS (data not shown). However, when we compared
the absolute expression levels of both S100A7a and
S100A7c by quantitative real-time PCR we found that
S100A7c was expressed at a 650-fold higher level than
S100A7a (12285836 vs. 193 mRNA copies per 1 g
of total RNA) (Supplemental Fig. 2B). Transcripts of
the third potentially functional S100A7 isoform,
S100A7b, could not be detected in KCs (Supplemental
Fig. 2B). These data suggest that S100A7a and S100A7c
are regulated by E. coli components in a similar man-
ner; however, S100A7c is expressed at a much higher
level.
Figure 1. Flagellin induces S100A7c and hBD-2 expression in
human primary KCs. Normal human epidermal KCs were
stimulated for 16 h with IL-1 (10 ng/ml) and the following
TLR ligands: 0.5 g/ml synthetic tripalmitoylated lipopeptide
(Pam3CSK4; TLR1/2 ligand), 108 cells/ml heat-killed Listeria
monocytogenes (HKLM; TLR2 ligand), 15 g/ml poly(I:C)
(a synthetic analog of double-stranded RNA; TLR3 ligand),
100 ng/ml ultrapure LPS from E. coli K12 (TLR4 ligand), 0.5
g/ml purified flagellin from S. typhimurium (TLR5 ligand),
0.5 g/ml FSL1 (a synthetic lipoprotein of M. salivarium;
TLR6/2 ligand), 10 g/ml imiquimod (R837; TLR7 ligand),
1 g/ml single-stranded RNA40 (ssRNA; TLR8 ligand), and
2.5 M ODN2006 (CpG oligonucleotide type B; TLR9 li-
gand). After stimulation, RNA was harvested and relative
S100A7c (A) and hBD-2 (B) gene expression levels were
quantified by real-time PCR and normalized to the expression
of the housekeeping gene -2-microglobulin. The mean
values are displayed in relation to untreated controls. Data
are means  sd of one representative experiment of three,
each done in triplicate. *P 	 0.05 vs. untreated control;
unpaired Student’s t test.
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Figure 2. Time- and dose-dependent effect of flagellin on S100A7c and hBD-2 expression. KCs were stimulated with the
indicated concentrations of flagellin for 24 h. Thereafter, quantitative real-time PCR analysis of S100A7c (A) and hBD-2
(B) mRNA expression was performed. KCs were cultured for the indicated times in the presence of 10 ng/ml flagellin, and
quantitative real-time PCR analysis of S100A7c (C), hBD-2 (D), and IL-8 (E) mRNA expression was performed. KCs were
stimulated with IL-1 or IL-8 (both at 10 ng/ml) for 24 h; after stimulation, relative S100A7c and hBD-2 gene expression
levels were determined by quantitative real-time PCR (F). All gene expression levels were normalized to the housekeeping
gene -2-microglobulin. The mean values are displayed in relation to untreated controls. Data are means  sd of one
representative experiment of three, each done in triplicate.
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Knockdown of TLR5 abolishes S100A7c and hBD-2
induction by E. coli
Flagellin is known to induce antimicrobial defense via
two pathways, namely activation of the intracellular
receptor ICE-protease-activating factor (Ipaf) followed
by caspase-1-mediated processing of IL-1 (51) and/or
binding to TLR5 and MyD88-dependent intracellular
signaling (24). Because our results obtained with the
IL-1Ra argued against a role of IL-1 and, accordingly,
also against a role of the Ipaf pathway (51), we focused
our further investigations on the putative role of TLR5
in the response of KCs toward E. coli. siRNA technology
was used to knock down TLR5 expression in KCs.
Transfection of KCs with TLR5 siRNA led to a down-
regulation of TLR5 mRNA by 70% compared with
siRNA with a scrambled sequence (Fig. 5A). Knock-
down of TLR5 strongly inhibited the induction of
S100A7c and hBD-2 mRNA by flagellin and WT E. coli
supernatant (Fig. 5B, C). Western blot analysis of cell
Figure 3. Flagellin induction of S100A7c and hBD-2 is IL-1-independent. A) KCs were stimulated with flagellin (10 ng/ml) for
the indicated times, and culture medium was measured for IL-1 secretion by ELISA. Data are means sd of one representative
experiment of two, each done in triplicate. B, C) KCs were preincubated for 90 min with anti-IL-1 (2 g/ml), with isotype
control (2 g/ml) or with IL-1Ra (100 ng/ml), as indicated. Afterwards, cells were treated with IL-1 or flagellin (both at 10
ng/ml) or left untreated for 24 h in the continued presence of the reagents used for preincubation. Relative gene expressions
of S100A7c (B) and hBD-2 (C) were quantitated by real-time PCR and normalized to the housekeeping gene -2-microglobulin.
The mean values are displayed in relation to untreated controls. Data are means of triplicates sd. Similar results were obtained
in a second experiment. *P 	 0.05, determined by unpaired Student’s t test. n.s., not significant.
Figure 4. FliC does not induce S100A7c or hBD-2 in human primary KCs. A, B)
Culture supernatants of WT and FliC E. coli strains and tryptic soy broth [control
(ctrl.)] were diluted 1:100 in KBM and added to KCs from which the previous culture
medium had been removed. Culture was continued for 16 h. After stimulation,
relative S100A7c (A) and hBD-2 (B) gene expression levels were determined by
quantitative real-time PCR. The results were normalized to the expression of the
housekeeping gene -2-microglobulin. Mean values are displayed in relation to the
control. Data are means  sd of triplicate samples from one representative of four
independent experiments. C) S100A7c and GAPDH Western blot analysis of cell
lysates after 48 h of stimulation with IL-1, flagellin (both at 10 ng/ml), and E. coli
culture supernatants (1:100 in KBM). The Western blot is representative of at least
four independent experiments. D) Culture medium was collected after 16 h of
stimulation, and the concentration of IL-8 was determined by ELISA. Data are
means  sd of triplicate samples from one representative of three independent
experiments. *P 	 0.05, unpaired Student’s t test.
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lysates showed that knockdown of TLR5 also sup-
pressed the increase of S100A7c protein production by
flagellin and WT E. coli supernatant (Fig. 5D).
DISCUSSION
S100A7c is one of the most potent antimicrobial agents
of the skin surface and it appears to be relatively
specific for E. coli (1). The fact that S100A7c is ex-
pressed in a focal pattern in the epidermis and the
finding that E. coli culture supernatants are able to
increase S100A7c abundance on human skin have
indicated that S100A7c is up-regulated by bacterial
substances entering the epidermis through micro-
wounds (1, 2). However, distinct exogenous molecular
triggers of S100A7c have remained elusive. In the
present study, we demonstrate that S100A7c is induced
by flagellin, a component of flagellated bacteria, in-
cluding E. coli.
A key result of this study was the demonstration that
flagellin deficiency of E. coli is associated with a lack of
induction of S100A7c. Because we compared two E. coli
strains that differed exclusively at the locus of the fliC
gene, which was destroyed by targeted deletion in E. coli
NK9375, mutations affecting other gene products can
be excluded as causative factors for the observed differ-
ence. Together with our demonstration that purified
flagellin is sufficient to induce S100A7c up-regulation,
the data obtained with E. coli supernatants strongly
suggest that flagellin is the only relevant E. coli compo-
nent that stimulates S100A7c expression in KCs. How-
ever, there remains the theoretical possibility that an as
yet unknown factor attaches to flagellin and contributes
to its effects. The ultimate proof may involve the use of
ultrapure flagellin or flagellin fragments produced by
peptide synthesis in vitro instead of purification from
flagellated bacteria or bacteria expressing recombinant
flagellin.
Complementary to our findings regarding the role of
bacterial flagellin in S100A7c regulation, we have iden-
tified the flagellin receptor TLR5 as an essential ele-
ment of the sensory and signaling system for E. coli in
KCs. Furthermore, our data also demonstrate that
TLR5 is critical for the induction of hBD-2. Compared
with the results of a previous report (52) that showed

7-fold up-regulation of hBD-2 promoter activity in
response to bacterial muramyl dipeptide (MDP), the
50- to 100-fold up-regulation of hBD-2 mRNA expres-
sion by flagellin observed in our study appears to be
more relevant in a physiological context. However, it is
conceivable that TLR5 on the KC membrane and
intracellular NOD2, the receptor of MDP, cooperate in
sensing E. coli and triggering hBD-2 expression.
S100A7c is up-regulated by flagellin more than 8 h
after stimulation of KCs. The response time from
addition of flagellin to the production of S100A7c
mRNA was longer than that for the induction of IL-8
but was comparable to the kinetics of S100A7c expres-
sion in KCs observed by others after stimulation with
various cytokines (1, 49). The exploration of the cause
for this relatively slow response exceeds the scope of
our present study. However, our data argue against a
role of autocrine activation of S100A7c production by
IL-1 and IL-8, because blockade of the former did not
inhibit flagellin-induced S100A7c expression and addi-
tion of the latter did not induce the expression of
S100A7c when added to KCs.
Our data on the regulation of S100A7c extend the
range of inducers of S100A7c in KCs. Previously, the
Figure 5. Knockdown of TLR5 abolishes the induction of S100A7c and hBD-2
by E. coli supernatant in human primary KCs. KCs were transfected either
with scrambled (scr; ) or TLR5 (f) siRNA. Forty-eight hours after
transfection, cells were stimulated with flagellin (10 ng/ml), culture super-
natants of WT and FliC E. coli strains or tryptic soy broth [control (ctrl.)]
diluted (1:100) in KBM. Sixteen or 48 h later mRNA and protein, respec-
tively, were prepared and analyzed. A–C) Relative expression of TLR5 (A),
S100A7c (B), and hBD-2 (C) was quantified by real-time PCR. The results
were normalized to the expression of the housekeeping gene -2-micro-
globulin. Mean values are displayed in relation to untreated controls. Data
are means  sd of triplicate samples from one representative of three independent experiments. D) S100A7c and GAPDH
Western blot analysis of TLR5 knockdown KC lysate stimulated for 48 h as indicated. The data are representative of three
independent experiments.
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cytokines IL-1, tumor necrosis factor-, IFN- (1),
IL-6, IL-17, IL-20, IL-22, IL-24, and oncostatin M (49),
as well as late states of KC differentiation (53), have
been shown to enhance the expression level of
S100A7c. The role of flagellin in the control of S100A7c
therefore needs to be further evaluated in combination
with other factors, many of which may be highly
relevant in the context of cutaneous wounds. Unfor-
tunately, the mouse is not a suitable model system for
the investigation of S100A7 regulation because the
mouse has lost the S100A7 genes during evolution
(50). The murine gene most closely related to S100A7
is S100A15, the ortholog of which has been lost during
human evolution (50). Although S100A15 may fulfill a
role in the mouse equivalent to that of S100A7 in
humans, the regulatory mechanisms of both genes are
likely to differ (18).
It is remarkable that the presence of the inducer of
S100A7c, flagellin, distinguishes E. coli from the non-
flagellated bacteria of the commensal skin microflora
(54, 55). The specific response of KCs to a flagellated
bacterium by induction of S100A7c and hBD-2 expres-
sion may exemplify a previously unappreciated ability
of the innate immune system to discriminate between
potentially harmful microbes and commensal bacteria.
In line with this concept, S100A7c has been shown to
exert virtually no bactericidal activity against the skin-
resident bacterium Staphylococcus epidermidis (1). Fur-
ther studies are necessary to determine whether the
antimicrobial defense of the skin is adapted to specifi-
cally respond to and attack opportunistic bacteria while
preserving the resident microflora.
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Abstract  
 
The antimicrobial defense of the skin is partially mediated by RNase 7, an abundant 
ribonuclease of the stratum corneum (SC). Here we investigated the expression and 
regulation of members of the RNase A family and of the endogenous RNase inhibitor 
(RI) protein in epidermal keratinocytes (KCs). RT-PCR screening revealed that KCs 
expressed not only RNase 7 but also RNase 5, which was previously shown to kill 
the yeast Candida albicans, as well as RNase 1, RNase 4 and RI. The mRNA and 
protein levels of RNase 5, RNase 7 and RI increased during KC differentiation. When 
RNase 5 and RNase 7 were incubated with RI in vitro, not only their ribonucleolytic 
activities but also their antimicrobial activities were strongly suppressed. 
Immunochemical analyses revealed that SC contains RNase 5 whereas RI was not 
detectable. Unlike recombinant RNase 5, recombinant RI was degraded when 
exposed to SC extract. The addition of aprotinin prevented the degradation of RI, 
indicating that serine proteases of the SC cleave RI. Taken together, this study adds 
RNase 5 to the list of antimicrobial factors present in the SC and suggests that 
proteases indirectly contribute to the defense function of the SC by releasing the RI-
mediated inhibition of RNase 5 and RNase 7.  
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Introduction 
 
The fact that the surface of human skin contains strong ribonuclease (RNase) 
activity is well known (Tabachnick and Freed, 1961; Steigleder and Raab, 1962). 
However, the physiological role of the skin ribonuclease activity and its control has 
not yet been characterized in depth. Recently, RNase 7 was isolated from human 
stratum corneum (SC), and was shown to exert antimicrobial activity (Harder and 
Schröder, 2002).  
RNase 7 is a member of the human RNase A superfamily, which is encoded by a 
cluster of thirteen genes located on chromosome 14q11.2. Only eight genes (RNases 
1 to 8) of this family encode for proteins which are catalytically active to varying 
degrees against standard RNA substrates (Dyer and Rosenberg, 2006). In addition to 
their ribonuclease activity, some members of this family such as RNase 2 
(eosinophil-derived neurotoxin; EDN), RNase 3 (eosinophil cationic protein; ECP), 
RNase 5, the above-mentioned RNase 7 and RNase 8 have antimicrobial properties 
as well (Domachowske et al., 1998; Lehrer et al., 1989; Hooper et al., 2003; Harder 
and Schröder, 2002; Rudolph et al., 2006), indicating a role in the innate immune 
defense. RNase 7 is active especially against Enterococcus faecium, Pseudomonas 
aeruginosa, and Pichia pastoris, and to a lesser degree against Propionibacterium 
acnes and E. coli (Harder and Schröder, 2002; Huang et al., 2007). It has been 
suggested that the antimicrobial activity of RNase 7 is due to pore formation and 
disruption of the bacterial membrane and is independent of the ribonuclease activity 
(Huang et al., 2007). RNase 5, also known as angiogenin, has been implicated in 
blood vessel formation (Fett et al., 1985), but a recent study revealed an antimicrobial 
activity of RNase 5 especially against Candida albicans (Hooper et al., 2003). RNase 
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5 is secreted by reconstructed human epidermis in vitro (Rendl et al., 2001), 
however, its contribution to the skin defense is unknown.  
Ribonuclease inhibitor (RI) is a horseshoe-shaped leucine-rich repeat protein 
(Kobe and Deisenhofer, 1993) which constitutes about 0.1% of the total protein in the 
cytosol of mammalian cells (Leland and Raines, 2001). Via its concave cavity, RI 
binds at a 1:1 stoichiometry to several members of the RNase A superfamily (Shapiro 
and Vallee, 1987; Maeda et al., 2002; Iyer et al., 2005; Johnson et al., 2007; Shapiro 
et al., 1986; Papageorgiou et al., 1997). RI has been shown to inhibit the enzymatic 
activity of RNases as well as the antiretroviral activity of RNase 2 (Domachowske 
and Rosenberg, 1997) and the angiogenic activity of RNase 5 (Shapiro and Vallee, 
1987). By contrast, the killing activity of RNase 3 towards microfilaria and 
trypanosomes is not blocked by RI (Hamann et al., 1990; Molina et al., 1988). 
Here we have investigated the regulation of RNase-RI interactions in the outer 
layers of the epidermis. We show that in vitro, the ribonuclease and antimicrobial 
activities of RNase 5 and RNase 7, which are both expressed by KCs and present in 
the SC, are sensitive to RI. Despite the fact that, like RNase 5 and RNase 7, RI is 
also up-regulated during terminal KC differentiation, it is virtually absent from normal 
SC. Co-incubation of RI and SC extracts revealed the existence of SC proteolytic 
activity able to degrade RI. We propose that by degrading RI, proteases of the SC 
contribute to the antimicrobial defense of the skin. 
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Materials & Methods 
 
Cell culture 
 
Human primary KCs prepared from neonatal foreskin were obtained from 
Clonetics (San Diego, CA) and cultured in serum-free keratinocyte growth medium 
(KGM, Clonetics) as described previously (Rendl et al., 2002). Third passage KCs 
were cultured in 12-well tissue culture plates (Corning Incorporated, Corning, NY) 
and used at a confluence of 60-70% (designated as proliferating) or maintained for 4 
days after reaching confluence (designated as differentiated) by replacing the 
medium every 24 hours. The differentiation state of KCs was confirmed by 
determination of the differentiation marker filaggrin. Cultures were grown in 
triplicates. For in vitro stimulation recombinant interleukin (IL)-1α and IL-6 (R&D 
Systems, Minneapolis, MN, USA) were used.  
 
RNA isolation, reverse transcription and PCR 
 
RNA was isolated using TRIzol® Reagent (Invitrogen, Carlsbad, CA) according to 
the manufacturer’s instructions. cDNAs were synthesized as described previously 
(Abtin et al., 2008). Briefly, RNA was reverse-transcribed with murine leukemia virus 
reverse transcriptase using the Gene Amp RNA PCR kit (Applied Biosystems, Foster 
City, CA) and oligo dT primers (Roche Diagnostics, Basel, Switzerland). cDNA 
sequences of the genes under investigation were obtained from the GenBank. 
Primers were designed using the PRIMER3 software from the Whitehead Institute for 
Biomedical Research (Cambridge, MA). The following forward (F) and reverse (R) 
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intron-spanning primers were synthesized by VBC Genomics (VBC Genomics, 
Vienna, Austria):  
RNase 1: F, 5′- GATTGCAGAAACTGGCCTTC-3′; R, 5′-
CTGGGGGAACTGTCTGAGTC-3′; RNase 2: F, 5′-CTGAACCCCAGAACAACCAG-
3′; R, 5′-GAGCCCAGGTAAACTGTGGA-3′; RNase 3: F, 5′-
AACAACCAGCTGGATCAGTTC-3′; R, 5′-CCACTGAGCCCTCGTAAACT-3′; RNase 
4: F, 5′-AGAAGCGGGTGAGAAACAAA-3′; R, 5′-AGTAGCGATCACTGCCACCT-3′; 
RNase 5: F, 5′-AGAAGCGGGTGAGAAACAAA-3′; R, 5′-
TGTGGCTCGGTACTGGCATG-3′; RNase 6: F, 5′-ATACACACAGGGCTCGAAGG-
3′; R, 5′-GGACACACTGGTCCCCATAG-3′; RNase 7; F, 5′-
GAGTCACAGCACGAAGACCA-3′; R, 5′-GGCTGCATGTGCTGAATTT-3′; RNase 8; 
F, 5′-CAGTGGTTTAAAACTCAGCATG-3′; R, 5′-ACTATGTAAGGTGTGTTCAGGT-
3′; RI; F, 5′-CATCAGCTCTGCACTTCGAG-3′; R, 5′-CAAGAGGTTGTCGCTGAGGT-
3′; B2M: F, 5′-GATGAGTATGCCTGCCGTGTG-3′; R, 5′-
CAATCCAAATGCGGCATCT-3′; ALAS: F, 5′-CCACTGGAAGAGCTGTGTGA-3′; R, 
5′-ACCCTCCAACACAACCAAAG-3′; human beta defensin-2 (hBD-2): F, 5′-
ATCAGCCATGAGGGTCTTGT-3′; R, 5′-GAGACCACAGGTGCCATTTT-3′. 
PCRs were performed in a volume of 50 µl containing 0.2 µl Red Hot® DNA 
polymerase (ABgene, Hamburg, Germany), 5 µl 10x reaction buffer IV (ABgene), 3 µl 
MgCl2 (25 mM), 4 µl dNTPs (2.5 mM), 2.5 µl of each primer (10 µM) and 31.8 µl H2O. 
The PCR included 5 minutes 94°C for initial denaturing followed by 38 cycles of 1 
minute at 94°C, 45 seconds at 60°C, 45 seconds at 72°C and a final extension step 
at 72°C for 5 minutes. A negative control (omitting cDNA) and a genomic DNA 
control PCR were performed for each primer pair. Amplicons were subjected to 
electrophoresis in a 1.5% agarose gel containing ethidium bromide. 
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Quantitative real-time PCR (qRT-PCR) was performed by the LightCycler 
technology using the Fast Start SYBR Green I kit for amplification and detection 
(Roche Diagnostics). In all assays, cDNA was amplified using a standardized 
program (10 minutes denaturing step and 55 cycles of 5 seconds at 95°C; 15 
seconds at 65°C, and 15 seconds at 72°C; melting point analysis in 0.1°C steps; final 
cooling step). Each LightCycler capillary was loaded with 1.5 µl DNA master mix, 1.8 
µl MgCl2 (25 mM), 10.2 µl H2O, and 0.5 µl of each primer (10 µM). Relative 
quantification of target gene expression and amplification efficiencies were performed 
using a mathematical model as described previously (Pfaffl, 2001). The expression of 
the target gene was normalized to the expression of the housekeeping genes 5-
aminolevulinic acid synthase (ALAS) and/or β-2-microglobulin (B2M). Similar target 
mRNA quantifications were obtained with either housekeeping gene as standard. All 
qRT-PCRs were performed in triplicate. The specificity of PCR reactions was 
confirmed by sequencing of the PCR products. For the identification of RNase 1 
variants, PCR products were cloned into a pCR®2.1-TOPO® plasmid (Invitrogen) 
according to the manufacturer’s instructions and clones with different insert lengths 
were sequenced. 
 
Quantification of RNase 5 and RNase 7 
 
Culture supernatants of KCs or SC extracts were depleted by centrifugation of 
insoluble cell fragments and stored at -20°C until analysis. The concentration of 
RNase 5 was determined by ELISA (R&D Systems) according to the manufacturer’s 
instructions. 
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The concentration of RNase 7 was determined with an in-house RNase 7 ELISA, 
which has been developed using affinity-purified goat RNase 7 antibodies as will be 
described elsewhere1. 
 
1 Könten, B., Gläser, R., Schröder, J.M., and Harder, J. (2008). RNase 7 contributes to the cutaneous 
defense against Enterococcus faecium. unpublished. 
 
Immunohistochemical analysis 
 
Normal human skin was kindly provided by the Department of Plastic Surgery, 
Medical University of Vienna, Austria. Immunohistochemical analysis was performed 
on paraffin-embedded, formalin-fixed skin sections (4 µm) using the indirect 
immunoperoxidase staining technique. Briefly, endogenous peroxidase activity of 
sections were blocked by 0.3% H2O2/PBS (pH 7.5) for 15 minutes, washed with PBS 
and then blocked for 30 minutes with 10% goat serum (PAA, Linz, Austria) diluted in 
2% BSA/PBS. A polyclonal rabbit IgG anti-porcine RI antibody (kindly provided by J. 
Hofsteenge, Friedrich Miescher-Institut, Basel, Switzerland) was used. This antibody 
cross-reacts with human RI (Blazquez et al., 1996). Before immunolabeling with anti-
RI or a rabbit IgG isotype control (Santa Cruz Biotechnology, Santa Cruz, CA) 
sections were pre-treated in ChemMate™ Target Retrieval Solution (Dako 
Cytomation, Glostrup, Denmark) in a microwave oven for 2 x 5 minutes at 500 W. 
The anti-RI antibody and/or rabbit IgG isotype control (both at 2 µg/ml) were diluted 
in 2% BSA/PBS and applied for 1 hour on sections at room temperature. After 
washing in PBS, slides were incubated with biotinylated goat anti-rabbit IgG (1:100, 
Vector Laboratories, Burlingame, CA) for 30 minutes, washed in PBS and then 
exposed to StreptABComplex/HRP (Dako Cytomation) for 30 minutes. The AEC 
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(aminoethylcarbazole) substrate system (Dako Cytomation) was used as the 
chromogen. Sections were counter-stained with hematoxylin. 
 
Ribonuclease activity assay  
 
Recombinant RNase 5 (R&D Systems), purified RNase 7 (Harder and Schröder, 
2002) or SC extract were pre-incubated with RI in 30 mM Tris (pH 7.5) containing 30 
mM NaCl in a total volume of 15 µl for 10 minutes at 37°C. Afterwards 1.5 µg of total 
RNA were added to the reactions and incubated for 5 minutes at 37°C. Then RNA 
loading buffer (Fermentas, Glen Burnie, MD) was added and the mixture was heated 
for 5 minutes at 65°C, cooled on ice and subsequently electrophoresed through a 1% 
agarose gel containing ethidium bromide. 
Ribonuclease activity of RNase 5 was blocked by pre-incubation with DEPC or 
benzopurpurin B (both from Sigma-Aldrich, Vienna, Austria) in 10 mM sodium 
phosphate buffer (pH 7.4) in a total volume of 15 µl for 1 hour at 37°C. 
 
Antimicrobial activity assay  
 
C. albicans ATCC 90028 and a vancomycin-resistant E. faecium clinical isolate 
were cultured overnight in tryptic soy broth (TSB; Fluka, Buchs, Switzerland) with 
agitation at 37°C, subcultured the next day in fresh TSB and then grown to optical 
densities of 1.0 at 600 nm for E. faecium or at 450 nm for C. albicans, respectively. 
Cells were washed twice with PBS and diluted to 104 colony-forming units (CFUs) per 
ml in 10 mM sodium phosphate buffer (pH 7.4) containing 1% (v/v) TSB.  
Recombinant human RNase 5 (> 95% purity) was purchased from R&D Systems 
and natural RNase 7 was purified from heel SC as described previously (Harder and 
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Schröder, 2002). Recombinant human RI was purchased from Ambion (Warrington, 
UK). The antimicrobial activity was tested using a microdilution assay system. Tubes 
were pre-incubated with 2% BSA/PBS for 1 hour at 37°C and were then rinsed with 
10 mM sodium phosphate buffer (pH 7.4) containing 1% (v/v) TSB. Since RI is 
provided with a storage buffer containing 20 mM HEPES-KOH (pH 7.6), 50 mM KCI, 
5 mM dithiothreitol and 50% (v/v) glycerol, the same buffer without RI was used in 
control reactions. For inhibitory activity experiments, RNase 5 or RNase 7 were pre-
incubated with buffer alone or with RI in 10 µl volumes of 10 mM sodium phosphate 
buffer (pH 7.4) for 1 hour at 37°C. 100 µl of the above-mentioned C. albicans or E. 
faecium suspensions were then added and incubated for 3 hours at 37°C with 
agitation. Afterwards, 20 µl aliquots were plated on Luria-Bertani agar or Sabouraud-
Dextrose agar for E. faecium and C. albicans, respectively. Plates were incubated 
overnight at 37°C. On the following day the number of CFUs was determined. The 
growth inhibitory activities of the substances were calculated as follows: (CFUs after 
incubation with substance) / (CFUs after incubation without substance) x 100, which 
represents the percentage of remaining CFUs after treatment. 
Antimicrobial activity and calculation of growth inhibition of recombinant RNase 5 
towards P. aeruginosa ATCC 27853, methicillin-resistant St. aureus ATCC 33592 
(MRSA), E. coli ATCC 35218 and a clinical isolate of group A Streptococcus (GAS) 
were performed as described above except that GAS was grown in TSB 
supplemented with 10 % heat-inactivated fetal calf serum. For the determination of 
CFUs, GAS was plated on Columbia agar, and P. aeruginosa, St. aureus and E. coli 
were plated on Luria-Bertani agar. 
To test whether RNase 5 antimicrobial activity is blocked by DEPC or 
benzopurpurin B, RNase 5 was pre-incubated in 10 µl volumes of sodium phosphate 
buffer (10 mM, pH 7.4) for 1 hour at 37°C with increasing concentrations of DEPC or 
  51
benzopurpurin B. 100 µl of the above-mentioned C. albicans suspension was then 
added and incubated for 3 hours at 37°C with agitation. The growth inhibitory effect 
was calculated as described above. 
 
SC extraction and incubation with RI 
 
SC obtained from heels of healthy volunteers was extracted with 100 mM 2-(N-
morpholino) ethanesulfonic acid (MES) buffer pH 7.5 (Sigma-Aldrich). A ratio of 25 
mg SC to 200 µl buffer was used. SC was homogenised in 1.5 ml tubes (Eppendorf, 
Hamburg, Germany) with a micropestle (Eppendorf) on ice (1-2 minutes) and then 
incubated for 1 hour rotating at 4°C. Thereafter, tubes were centrifuged with 15000 g 
for 20 minutes at 4°C. Subsequently, the supernatant was aliquoted and stored at -
20°C until analysis. Sterility was verified by plating extracts on blood agar. Protein 
concentrations of SC extracts were measured by the bicinchoninic acid method 
(BCA; Pierce, Rockford, IL).  
10 µg SC extract were co-incubated with 20 units (U) recombinant human RI or 
50 ng recombinant RNase 5 (R&D Systems) at 37°C with agitation. The final reaction 
volume was 30 µl. Aliquots of SC were pre-incubated for 90 minutes at 37°C with the 
following protease inhibitors: complete protease inhibitor cocktail (EDTA free), 
leupeptin, aprotinin (all from Roche Diagnostic), EDTA pH 7.5 (Merck, Darmstadt, 
Germany) and GM6001 (Calbiochem, Inc., La Jolla, CA, USA). 
 
Western blot analysis 
 
For analysis of RI expression, KC monolayer cultures were lyzed in 1% Nonidet 
P-40 (Igepal CA-630) (Sigma-Aldrich), and insoluble cell debris was removed by 
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centrifugation. The epidermis of skin biopsies was separated by dispase II (30 min 
37°C; Roche Diagnostic) from the dermis. Afterwards epidermis and/or heel scales 
were quick-frozen with liquid nitrogen, ground in a mortar and suspended in 100 mM 
MES pH 7.5 and left rotating for 1 hour at 4°C. Thereafter, samples were centrifuged 
(15000 g for 20 minutes at 4°C) and the supernatant was aliquoted. The protein 
concentration was measured by the BCA method (Pierce). Western blot analysis was 
performed as described previously (Mildner et al., 2006). Equal loading of protein 
lysates was confirmed by Ponceau staining of the membrane. Rabbit anti-RI antibody 
was used for detection of RI protein (dilution 1:3000). A peroxidase-conjugated goat 
anti-rabbit IgG antibody (dilution 1:10000, Pierce) was used as a secondary antibody. 
Mouse anti-caspase-14 (dilution 1:1000, MBL, Naka-ku Nagoya, Japan) was used for 
the detection of the proform and the active form of caspase-14 with a secondary 
peroxidase-conjugated sheep anti-mouse IgG antibody (dilution 1:10000, Amersham, 
Buckinghamshire, UK). For RNase 5 detection a polyclonal goat antibody (R&D 
Systems) and a secondary peroxidase-conjugated rabbit anti-goat (dilution 1:10000, 
Dako Cytomation) antibody were used.  The membranes were developed using the 
Chemiglow reagent (Alpha Innotech, San Leandro, CA) according to the 
manufacturer’s instructions. 
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Results 
 
Epidermal KCs express RNases 1, 4, 5 and 7 as well as RI 
 
To provide the basis for a better understanding of the potential roles of RNase–RI 
interactions in the skin, we determined the mRNA expression profile of RNases 1 to 8 
and of RI in cultured epidermal KCs. RNases 1, 4, 5 and 7 as well as RI were 
detected by reverse transcription-PCR (RT-PCR) whereas other RNases were not. 
RNases 4, 5 and 7 were expressed in both proliferating (data not shown) and in 
differentiated KCs (Figure 1a). Differentiated KCs also expressed RNase 1 splice 
variants 2 (lower band, GenBank acc. no. NM198234) and 4 (upper band, GenBank 
acc. no. NM002933), which differ in the 5´-untranslated region but code for the same 
protein. For RNase 4, splice variant 2 (GenBank acc. no. NM002937) and for RNase 
5, splice variant 1 (GenBank acc. no. NM001145) could be amplified (Figure 1a, 
upper panel). The identity of the PCR products was determined by direct sequencing 
and the integrity of the assays for RNases 2, 3, 6 and 8, which were not detected at 
the cDNA level, was confirmed by PCR amplification using genomic DNA as a 
template (Figure 1a, lower panel). The expression of RNases 9 to 13 was not 
investigated, since they do not have all elements to support ribonuclease activity 
(Dyer and Rosenberg, 2006).  
Focusing on RNases with antimicrobial activities (Harder and Schröder, 2002; 
Hooper et al., 2003), we investigated the regulation of RNase 5 and RNase 7 during 
KC differentiation. By quantitative real-time PCR (qRT-PCR), we found that the 
expression of RNase 5 and RNase 7 mRNAs were up-regulated 4- and 9-fold, 
respectively, in differentiated cultures compared to proliferating KCs (Figure 1b, c). 
The concentrations of secreted RNase 5 and RNase 7 proteins were determined by 
  54
enzyme-linked immunosorbent assay (ELISA). Culture medium conditioned by 
differentiated KCs for 24 hours contained approximately 4- and 6-fold higher levels of 
RNase 5 and RNase 7, respectively, than medium conditioned by proliferating cells 
(Figure 1d, e). Since the cell biomass, estimated by protein quantification, was 
elevated by only 1.7-fold (data not shown), these data show that the production of 
RNase 5 and RNase 7 was up-regulated during differentiation of KCs. The absolute 
concentration of secreted RNase 5 was smaller than that of RNase 7 (Figure 1d, e). 
Similarly, the amount of soluble RNase 5 that we could extract from SC of human 
heels, i.e. 57 ± 38 pg per mg SC, was much smaller than the amount of RNase 7 that 
has been extracted from SC of different donors, i.e. up to 6000 pg per mg SC (Harder 
and Schröder, 2002). 
 
RI is expressed in the epidermis but is absent in SC 
 
We next investigated the expression of RI in human skin (n=5) by 
immunohistochemistry. RI was expressed in all viable layers of the epidermis, with 
the strongest expression being detectable in the uppermost layers of the epidermis. 
By contrast, RI immunoreactivity was not detectable in the SC (Figure 2a).  
The expression of RI during KC differentiation in vitro was investigated by qRT-
PCR and Western blot analysis. RI was up-regulated at both the mRNA (Figure 2b) 
and protein level (Figure 2c) in differentiated versus proliferating KCs. 
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RI blocks ribonuclease activity of SC as well as the antimicrobial activity of 
RNase 5 and RNase 7 
 
In accordance with a previous report (Probst et al., 2006), we readily detected 
ribonuclease activity in SC extracts. Addition of recombinant human RI virtually 
abrogated this activity, suggesting that the RNases of the SC can be bound and 
neutralized by RI (Figure 3a). Moreover, RI blocked the ribonuclease activity of 
recombinant RNase 5 and purified RNase 7 from SC in vitro, confirming the 
functionality of our proteins (Figure 3b). 
Next we tested whether RI is also able to interfere with the antimicrobial activities 
of RNase 5 and RNase 7 against C. albicans and E. faecium, respectively (Hooper et 
al., 2003; Harder and Schröder, 2002). In the absence of RI, antimicrobial activity of 
RNase 5 and RNase 7 strongly reduced the colony-forming units (CFUs) of C. 
albicans and E. faecium, respectively. Pre-incubation with RI strongly suppressed the 
antimicrobial activity of both RNases, whereas addition of RI alone had no effect on 
either microbe (Figure 4a, b). These results demonstrate, for the first time, that RI not 
only blocks ribonuclease activity but also suppresses the antimicrobial activity of 
RNase 5 and RNase 7. 
 
The antimicrobial effect of RNase 5 is blocked by chemical inhibitors of its 
ribonuclease activity 
 
Since RI interacts with a large portion of the surface of target RNases  
(Papageorgiou et al., 1997) and not specifically with the catalytic centre, the blockade 
of antimicrobial activities of RNase 5 and RNase 7 may be mediated by the 
interference with the RNase catalytic activity or by sterical blockade of a bactericidal 
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protein domain. The antimicrobial activity of RNase 7 is mediated by a cluster of 
lysine residues and does not depend on catalytic activity (Huang et al., 2007). Amino 
acid sequence alignment showed that the residues critical for the antibacterial activity 
of RNase 7 are not conserved in RNase 5 (Figure S1). Therefore, we hypothesized 
that RNase 5 utilizes a different mechanism, possibly involving its ribonucleolytic 
activity to kill Candida. RNase 5 was pre-incubated with two chemical inhibitors of its 
ribonuclease activity, namely diethylpyrocarbonate (DEPC) (Shapiro et al., 1987) and 
benzopurpurin B (Jenkins and Shapiro, 2003). As expected, both substances 
inhibited the degradation of RNA by RNase 5 in a dose-dependent manner (Figure 
5a, b). In close correlation with this blockade, both DEPC and benzopurpurin B also 
inhibited the candida-cidal activity of RNase 5 (Figure 5c, d), indicating that the 
antimicrobial effect of RNase 5 depends on its ribonucleolytic activity. 
To further characterize the antimicrobial potential of RNase 5, we also tested 
Pseudomonas aeruginosa, Escherichia coli, methicillin-resistant Staphylococcus 
aureus (MRSA), Enterococcus faecium and group A Streptococcus (GAS) for their 
sensitivity towards RNase 5 treatment. However, among the microorganisms 
investigated, RNase 5 was only effective at killing C. albicans (Figure S2). To 
evaluate whether enhancement of expression of RNase 5 might contribute to the 
control of its antimicrobial activity, KCs were stimulated with heat-inactivated C. 
albicans or with the proinflammatory cytokines, interleukin (IL)-1α and IL-6. Neither 
treatment altered the expression of RNase 5 in KCs (Figure S3). Similarly, the 
expression of the RNase 5 inhibitor, RI, was not changed by proinflammatory stimuli 
(Figure S3). 
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RI is degraded by SC extract 
 
Since immunohistochemistry suggested that RI, although present in the viable 
epidermal layers, was absent from SC (Figure 2a), we extracted proteins from the 
total epidermis and from SC alone and performed Western blot analysis. RI was 
detected in lysates of the epidermis but, confirming the immunohistochemistry data, 
was absent in SC extracts (Figure 6a). The integrity of SC extract was confirmed by 
Western blot analysis of caspase-14, which was readily detectable in its mature form 
(Figure. 6a) (Fischer et al., 2004).  
The fact that only the viable layers of the epidermis but not the SC contained RI 
indicated the existence of a mechanism to eliminate RI during conversion of KCs into 
corneocytes. To investigate this hypothesis, recombinant human RI was co-incubated 
with SC extracts and then analyzed by Western blot. Under these conditions RI 
protein was degraded, with an intermediate cleavage product of RI being detectable 
(Figure 6b). Incubation of RI alone with the extraction buffer demonstrated stability of 
the protein under assay conditions. To investigate which types of enzymes are 
responsible for RI degradation, SC extracts were pre-treated with various protease 
inhibitors (i.e. aprotinin for serine proteases, leupeptin for thiol proteases, EDTA and 
GM6001 for metalloproteases, and a protease inhibitor cocktail (EDTA free) for 
serine and cysteine proteases) and then analyzed for their ability to degrade RI. The 
inhibitor cocktail as well as aprotinin and EDTA inhibited proteases from degrading RI 
(Figure 6b). Notably, EDTA was not effective at a concentration, that is considered 
sufficient to block metalloproteases, but only at a concentration, at which EDTA also 
interferes with the activity of some serine proteases (Beynon and Bond, 2001). The 
metalloprotease-specific inhibitor, GM6001, showed virtually no inhibition. This 
inhibition profile suggested that serine proteases are mainly accountable for RI 
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degradation by SC extracts. In contrast to RI, recombinant RNase 5 was stable when 
co-incubated with SC extracts (Figure S4). 
 
Discussion 
 
In this study, we have explored the expression of all functional members of the 
RNase A superfamily, as well as of RI in epidermal KCs and propose that differential 
breakdown of RI during SC formation contributes to the antimicrobial activity of the 
skin surface. Our expression screening showed that 4 members of the RNase A 
family are expressed by KCs. Two of these RNases, namely RNase 5 and RNase 7, 
act as antimicrobial proteins whereas no such activity has been reported for RNase 1 
and RNase 4. This study is the first to demonstrate the presence of RNase 5 in 
human SC and thereby establishes another antimicrobial factor of the skin defense 
against microbes. Similar to RNase 7, RNase 5 was up-regulated during 
differentiation. However, proinflammatory or microbial inducers of expression could 
thus far be identified for RNase 7 only (Harder and Schröder, 2002). The rate of 
production of RNase 7 was approximately 5 times higher than that of RNase 5 in 
cultured KCs, and much higher amounts of RNase 7 than RNase 5 could be 
extracted from human SC, indicating that RNase 7 contributes more to the 
ribonucleolytic and antimicrobial activities of the skin surface. Nevertheless, it is 
conceivable that the local concentration of RNase 5, within distinct SC 
microcompartments may be sufficient for effective antimicrobial activity. 
Importantly, the antimicrobial activity spectra of RNase 5 and RNase 7 appear to 
differ significantly. In particular, C. albicans is killed by low concentrations of RNase 5 
(Hooper et al., 2003); this study) but much less effectively by RNase 7 (Harder and 
Schröder, 2002) whereas several bacteria are killed by RNase 7 (Harder and 
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Schröder, 2002) and not by RNase 5 (this study). The relative contribution of RNase 
5 to the innate immune defense of the skin, which is mediated by a plethora of 
peptides and other substances (Schröder and Harder, 2006), remains to be 
determined in future studies. 
Our study provides the first characterization of endogenous RI in the epidermis 
and, importantly, extends its range of functions to the inhibition of RNase 
antimicrobial activities. Both the candida-cidal activity of RNase 5 and the 
enterococcus-cidal activity of RNase 7 were effectively blocked by recombinant RI. 
Previous reports have shown that RI suppresses the ribonuclease activity, which is 
low as compared to other members of the RNase A family, and the angiogenic 
activity of RNase 5 (Shapiro and Vallee, 1987; Maeda et al., 2002; Iyer et al., 2005; 
Johnson et al., 2007; Shapiro et al., 1986; Papageorgiou et al., 1997). Two small 
chemical substances, DEPC and benzopurpurin B, which inhibit the catalytic activity 
of RNase 5, also suppressed its antimicrobial activity. The binding site of 
benzopurpurin B on RNase 5 has been determined (Jenkins and Shapiro, 2003) 
whereas the various RNase 5 subsites, likely to be targeted by DEPC via 
modification of lysine and histidine residues, have not been investigated for their 
individual contribution to the inhibitory effect of DEPC. Therefore, it appears likely 
that RI suppresses the antimicrobial function of RNase 5 by inhibiting its catalytic 
centre. However, further studies using point-mutated variants of RNase 5 are 
required to substantiate this hypothesis.    
Although the antimicrobial activity of RNase 7 does not depend on ribonucleolytic 
activity (Huang et al., 2007), our data demonstrate that it is suppressed by RI. There 
are two possible explanations for this finding: (1) It is possible that RI, which has a 
horseshoe-like shape and binds RNases within its concave cavity, masks the amino 
acid residues responsible for antimicrobial action. (2) The interaction of RI with 
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RNase 1 has recently been shown to induce conformational changes of RNase 1 
(Johnson et al., 2007). Since the interaction of RI and RNase 7 is likely to occur in a 
similar manner, a conformational change might also abrogate the antimicrobial 
activity of RNase 7. 
The finding that RI is expressed strongly in the uppermost layers of the epidermis 
but is absent in SC and the fact that SC contains ribonuclease activity and 
antimicrobial activity of RNase 7 (Harder and Schröder, 2002), indicated that a 
physiological mechanism exists to prevent inhibition of skin surface ribonuclease 
functions. In support of this hypothesis, the results of our co-incubation experiments 
using recombinant RI and SC extract showed degradation of RI. Our finding that 
aprotinin blocked the degradation of RI indicates that this breakdown is mediated by 
serine proteases such as SCTE (stratum corneum tryptic enzyme, kallikrein5) or 
SCCE (stratum corneum chymotryptic protease, kallikrein7). EDTA, which scavenges 
divalent cations, also blocked the reaction, however, only when it was used at a 
concentration higher than that required to block metalloproteases but sufficient to 
also inhibit some serine proteases (Beynon and Bond, 2001). Further studies are 
necessary to determine the molecular identity of the RI-degrading protease(s). 
The proteolysis of RI by SC proteases establishes a role of proteases in the 
antimicrobial defense function of the skin. Conceptually, this control mechanism 
resembles the control of the pro-apopototic DNase CAD/DFFB by the inhibitor 
ICAD/DFFA. ICAD inhibits CAD unless it is cleaved by the cysteine protease 
caspase-3 (Sakahira et al., 1998). It remains to be investigated whether proteolysis of 
RI enhances the breakdown of cellular RNAs during differentiation-associated 
programmed cell death of KCs. Irrespective of this potential role in cellular 
remodelling, breakdown of RI appears to facilitate the activities of RNase after 
corneocyte formation. A more direct dependence on proteases of protein activation in 
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the SC has been demonstrated for cathelicidin, which is converted to the 
antimicrobial peptide LL-37 by the action of the serine proteases kallikrein 5 (SCTE) 
and kallikrein 7 (SCCE) (Yamasaki et al., 2006). The processing of cathelicidin by 
these proteases does not require a distinct stimulus and leads to the constitutive 
presence of LL-37 on the skin surface (Yamasaki et al., 2006). Similarly, the 
proteolytic degradation of RI is likely to occur in a constitutive manner. Taken 
together, the disturbance of SC proteolytic activities, either caused by genetic defects 
or environmental influences, may compromise antimicrobial skin defence.  
In summary, this study identifies RNase 5 as a component of the innate immune 
system of the skin and reveals a novel level of regulation of antimicrobial RNases in 
human SC, i.e. the removal of their inhibitor by proteases.  
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Figure 1. KCs express RNases 1, 4, 5 and 7 as well as RI. 
 
Total RNA was isolated from proliferating (prolif.) and differentiated (diff.) human KC 
cultures and reverse-transcribed to cDNA. (a) cDNAs of differentiated KCs were 
amplified by PCRs specific for RNases 1 through 8 and for RI. Amplicons were 
separated on a 1.5% agarose gel containing ethidium bromide. To confirm the 
efficiency of each PCR, reactions with the same primer combinations were performed 
on genomic DNA. In these control reactions, exonic and intronic sequences of all 
genes except RNases 4 and 5, in which the primer annealing sites are separated by 
a long intron, were successfully amplified (lower panel). RNase 5 (b) and RNase 7 (c) 
expression in KCs was determined by qRT-PCR. Relative gene expression levels 
were normalized to the expression of the housekeeping gene ALAS. The mean 
values of the expression levels relative to the expression level in proliferating cells 
are displayed. Secretion of RNase 5 (d) and RNase 7 (e) of proliferating and 
differentiated KCs was determined by ELISAs. Data represent the mean ± SD. bp, 
base pair. 
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Figure 2. RI is expressed in the epidermis and in cultured KCs. 
 
(a) RI was detected by immunohistochemistry in normal human skin. An isotype 
antibody was used as negative control (ctrl.). The outer border of the SC is marked 
by a dotted line. Bars=40 µm. (b) qRT-PCR of RI in proliferating (prolif.) and 
differentiated (diff.) KCs. Relative gene expression levels were normalized to the 
expression of the housekeeping gene ALAS. Data represent the mean ± SD. (c) 
Western blot analysis of RI in proliferating and differentiated KCs (left panel). 
Ponceau staining of the membrane served as loading control of protein lysates (right 
panel). MW, molecular weight; RI, ribonuclease inhibitor. 
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Figure 3. Ribonuclease activities of SC extract, RNase 5 and RNase 7 are 
blocked by RI. 
 
(a) SC extract (30 ng), (b) RNase 5 (25 ng) and RNase 7 (5 ng) were pre-incubated 
with or without RI (30 U for SC extract and 40 U for RNase 5 and RNase 7). 
Subsequently, the mixtures were incubated with total RNA (1.5 µg) prepared from 
KCs as described in the Materials and Methods section. Thereafter samples were 
electrophoresed through an RNase-free agarose gel containing ethidium bromide. 
Positions of the 28S, 18S, 5S rRNA bands are indicated. U, units.  
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Figure 4. RI inhibits antimicrobial activity of RNase 5 and RNase 7. 
 
(a) RNase 5 (0.2 µM) or (b) RNase 7 (0.33 µM) were incubated with and without RI 
(40 and 20 U for RNase 5 and RNase 7, respectively) and then tested for their ability 
to inhibit the growth of C. albicans or E. faecium, respectively. In addition, C. albicans 
or E. faecium were treated with buffer and RI only. The results are displayed as 
percent of remaining CFUs in relation to untreated controls (100%). Data represent 
the mean of triplicates ± SD. CFU, colony-forming units. 
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Figure 5. Antimicrobial effect of RNase 5 depends on its ribonuclease activity.  
 
(a) Ribonuclease activity of RNase 5 (0.6 µM) was tested in the presence of  
diethylpyrocarbonate (DEPC) or (b) benzopurpurin B (BP) as described in the 
Materials and Methods section. Positions of the 28S, 18S, 5S rRNA bands are 
indicated. (c) RNase 5 (0.2 µM) was pre-incubated with DEPC or (d) BP and 
thereafter tested for its ability to inhibit the growth of C. albicans. The results are 
displayed as percent of remaining CFUs in relation to only DEPC or BP treated 
controls (100%). Data represent the mean of triplicates ± SD.  
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Figure 6. RI is absent in the SC and is degraded by SC extract. 
 
(a) Epidermis and SC were extracted as described in the Materials and Methods 
section and subjected to Western blot analysis for RI and caspase-14 (C14). 
Positions of a molecular weight (MW) marker are indicated on the right. Note that the 
SC contains only the mature form of caspase-14 (Fischer et al., 2004) whereas both 
pro-caspase-14 (pro-C14) and mature caspase-14 are present in total epidermis. (b) 
SC extract were pre-incubated with increasing concentrations (1 to 100 µM) of the 
protease inhibitors aprotinin, leupeptin, EDTA, GM6001 or complete protease 
inhibitor cocktail, EDTA free (complete; 1x to 3x) and subsequently incubated with RI, 
as described in the Materials and Methods section. RI was detected by Western blot 
analysis. prot. inhib., protease inhibitor. c-RI, cleaved RI protein. 
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Figure S1. Amino acid sequence alignment of RNase 5 and RNase 7. 
 
Residues critical for the antimicrobial activity of RNase 7 (Huang et al., 2007) are 
shown as white letters on black background. The signal peptide of RNase 5, which is 
missing in the mature protein, is underlined. 
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Figure S2. Antimicrobial activity of RNase 5 against potential skin pathogens.  
 
Antimicrobial activity of increasing concentrations of RNase 5 was tested against 
Gram-positive ( E. faecium, GAS and MRSA) and Gram-negative ( P. aeruginosa and 
E. coli) bacteria and the yeast C. albicans . Data represent the mean of triplicates ± 
SD. 
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Figure S3. RNase 5 and/or RI are not induced by IL-1α, IL-6 or C. albicans. 
 
Proliferating KCs were stimulated for 6, 12 and 24 hours (h) with (a) IL-1α or IL-6 
(both at 10 ng/ml) and (b) with heat-inactivated C. albicans (107 CFUs/ml). After 
stimulation RNA was isolated and the relative gene expressions of RNase 5, RI 
and/or human beta defensin-2 (hBD-2) were determined by qRT-PCR. Relative gene 
expression levels were normalized to the expression of the housekeeping gene 
ALAS. Data represent the mean ± SD. The induction of hBD-2 in (a) served as a 
control response to IL-1α and IL-6 stimulation. 
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Figure S4. RNase 5 is not degraded by SC extract. 
 
RNase 5 (50 ng) was incubated with and without SC (10 µg protein) extract for the 
indicated times and detected by Western blot analysis. 
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5. Discussion 
5.1. The role of flagellin in S100A7c expression by KCs. 
S100A7c has been found to be expressed in patchy pattern in the epidermis (Gläser et 
al., 2005; Schröder and Harder, 2006), indicating that it may be up-regulated by external 
substances entering the epidermis through microwounds. However, distinct exogenous 
molecular triggers of S100A7c have remained elusive. Our demonstration that flagellin 
induces S100A7c strongly supports the concept that the expression of S100A7c is indeed 
positively up-regulated in response to bacteria. The finding that flagellin but no other 
bacterial components trigger S100A7c expression makes physiological sense, because 
the most potent antimicrobial activity of S100A7c is directed to E. coli, a flagellated 
bacterium (Gläser et al., 2005). Our results show that S100A7c is induced by 
concentrations of flagellin that are only slightly higher than those necessary for the 
induction of hBD-2, another antimicrobial peptide. Although it is difficult to estimate the 
concentration of flagellin on the skin surface, it is likely that any focal growth of flagellated 
bacteria will be associated with sufficiently high concentration of flagellin. Nevertheless, 
the relevance of flagellin in the induction of S100A7c and hBD-2 remain to be investigated 
in vivo.  
 The potent E. coli-cidal activity of S100A7c might explain the inability of E. coli in 
colonizing healthy human skin. Indeed, an important in vivo function of S100A7c has 
demonstrated that E. coli is effectively killed on human skin and that this killing activity was 
reduced by a neutralizing antibody to S100A7c in vivo (Gläser et al., 2005). Gene-deficient 
murine models have demonstrated that lack of a single antimicrobial peptide makes mice 
more susceptible to infections. For example, mice deficient in the expression of CRAMP 
(the mouse homologue to the human cathelicidin) were more susceptible to skin infections 
caused by group A Streptococcus (GAS) (Nizet et al., 2001). These mice were also 
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susceptible to urinary tract infections caused by uropathogenic E. coli (Chromek et al., 
2006).  
A key result was the demonstration that flagellin expression by E. coli strain was 
associated with the regulation of S100A7c. We show that a flagellin-deficient E. coli strain 
(∆FliC) was unable to up-regulate the expression of S100A7c compared to wild-type 
strain. The finding that flagellin induces S100A7c expression and the data observed with 
the flagellin-deficient E. coli strain strongly suggest that flagellin is the only relevant E. coli 
component accountable for S100A7c stimulation in KCs.   
With regard to possible mechanisms, we have identified the flagellin receptor TLR5 
as an essential element of sensory and signaling system for E. coli. By using RNA 
interference technology, knock-down of TLR5 in KCs dramatically reduced responsiveness 
to E. coli, suggesting that the presence of E. coli is recognized by TLR5 and therefore a 
successful elimination is TLR5-dependent. In line with this concept, the significance of 
TLR5 for E. coli recognition was demonstrated in a murine model in vivo (Andersen-Nissen 
et al., 2007; Uematsu et al., 2006) where Tlr5-/- mice were more susceptible to urinary tract 
infections caused by uropathogenic E. coli compared to wild-type mice (Andersen-Nissen 
et al., 2007).  
Our data on the regulation of S100A7c extend the range of inducers of S100A7c in 
KCs. Previously, the cytokines IL-1β, TNF-α, IFN-γ (Gläser et al., 2005), IL-6, IL-17, IL-20, 
IL-22, IL-24 and oncostatin M (Boniface et al., 2007), as well as late states of KC 
differentiation (Martinsson et al., 2005) have been shown to enhance the expression level 
of S100A7c. Therefore, the role of flagellin in the control of S100A7c needs to be further 
evaluated in the combination with other factors, many of which may be highly relevant in 
the context of cutaneous wounds. Unfortunately, the TLR5 knockout mouse (Uematsu et 
al., 2006) is not a suitable model system because mice lack a S100A7 gene (Hahn et al., 
2007). Since S100A7 and S100A15 have evolved from a common ancestral gene (Hahn et 
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al., 2007) which may have had antimicrobial activity and it is conceivable that S100A15 
fulfils an equivalent role in the mouse as S100A7 in humans, the regulation of S100A15 
may serve as a model to study the concept of cutaneous defense against bacteria. 
Ultimately, the antimicrobial function and the regulation of S100A7 remain to be tested in 
humans or primates.  
In conclusion, the first part of the dissertation sheds light on the mechanism by 
which KCs sense and respond to the presence of E. coli. We show that a single bacterial 
component, i.e. flagellin is essential and sufficient to induce the up-regulation of the anti-
bacterial defense protein S100A7c, which is able to kill E. coli. Since E. coli is to be 
considered a model for flagellated Gram-negative bacteria, including skin pathogens such 
as Pseudomonas aeruginosa (Schröder and Harder, 2006), our results provide important 
new insights into the cutaneous antimicrobial defense system. 
 
5.2. SC proteolytic activity in establishing RNase-dependent 
antimicrobial functions. 
The microbial defensive function of the skin is partly mediated by antimicrobial 
peptides such as human β-defensins, S100A7c, cathelicidin and also by RNase 7 a 
member of the RNase A superfamily (Schröder and Harder, 2006). In the second part of 
the dissertation, we explored the expression of all functional members of the RNase A 
superfamily as well as of RI in epidermal KCs. Our expression screening showed that 4 
members of the RNase A family namly RNases 1, 4, 5 and the previously described 
RNase 7 are expressed by KCs. Two of this RNases i.e. RNase 5 and RNase 7 act as 
antimicrobial peptides, but until now no such activity has been described for RNase 1 and 
RNase 4.  
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This study is the first to demonstrate the presence of RNase 5 in human SC and 
thereby establishes another antimicrobial factor of the skin defense against microbes. The 
relative contribution of RNase 5 to the antimicrobial defense of the skin needs to be 
evaluated in further studies. The higher concentration of RNase 7 in SC compared to 
RNase 5 [4000 pg/mg SC (Harder and Schröder, 2002) vs. 60 pg/mg SC (our study)] 
suggests a prominent role in skin defense for RNase 7. Nevertheless, it is conceivable that 
local concentrations of RNase 5 might be sufficiently high for effective antimicrobial 
activity; especially against C. albicans which is sensitive to RNase 5 in very low 
micromolar concentrations (Hooper et al., 2003). However, RNase 5 is a multifunctional 
protein with ribonuclease, microbicidal and angiogenic properties but its key function in the 
skin has to be investigated in future studies. 
Our study provides the first characterization of endogenous RI in the epidermis and, 
importantly, extends its range of functions to the inhibition of RNase antimicrobial 
activities. RI suppresses ribonuclease activities of RNases (Iyer et al., 2005; Johnson et 
al., 2007), but also contributes to intracellular redox homeostasis (Monti et al., 2007). The 
finding that RI is expressed strongly in the uppermost layers of the epidermis but is absent 
in SC and the fact that SC contains ribonuclease and antimicrobial activity indicate that a 
physiological mechanism may exists to prevent inhibition of skin surface ribonuclease and 
probably antimicrobial functions. In support with this hypothesis, co-incubation of 
recombinant RI with SC extract led to degradation of RI. This degradation could be 
blocked by the serineprotease inhibitor aprotinin. Furthermore, it needs to be considered 
RI can also be predisposed to degradation, at least within the intracellular environment, by 
oxidation of its thiol groups (Blazquez et al., 1996). Oxidation of RI at the skin surface may 
contribute to the inactivation of RI. 
The significance of RI degradation was underlined with an in vitro experiment where 
the antimicrobial functionality of RNase 5 and RNase 7 were assessed in the presence of 
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RI. Interestingly, RI not only blocked the ribonuclease activity of these RNases, but also 
strongly suppressed their antimicrobial activity as well, indicating that presence of active RI 
in SC would interfere with the natural innate immune defense of skin-derived RNases. The 
inhibition of antimicrobial action by RI might be explained by conformational interaction of 
enzyme·inhibitor complex. RI has a horseshoe-shape structure and binds RNases within 
its concave cavity. Hence, it is likely that RI covers residues (active sites) responsible for 
antimicrobial action may lead to inactivity of this function. Although it has been reported 
that ribonuclease activity of RNases is not essential for their antimicrobial properties (Dyer 
and Rosenberg, 2006; Huang et al., 2007), it is possible that RI, covers active sites for 
both functions. Alternatively or in addition, the recently reported ability of RI to induce 
conformational changes of RNase 1 upon formation of a complex with this protein 
(Johnson et al., 2007) might suggest that conformations of RNase 5 and RNase 7 which 
are incompatible with antimicrobial activity, may be induced by RI.  
The proteolysis of RI by SC proteases establishes an indirect role of proteases in the 
antimicrobial defense function of the skin. A direct dependence on proteases of protein 
activation in the SC has been demonstrated for cathelicidin, which is converted to the 
active antimicrobial peptide LL-37 by the action of the serine proteases kallikrein 5 and 
kallikrein 7 (Yamasaki et al., 2006). This suggests a two steps processing for an efficient 
antimicrobial activity of cathelicidin. The first step is on transcriptional level where the 
cathelicidin gene is transcribed and then translated to its protein precursor hCAP18, the 
second step appears on post-translational level with the enzymatic modification of the 
precursor to the active antimicrobial LL-37. A similar mechanism might be considered for 
the activity of RNase 7 and/or RNase 5 where RI is degraded on post-translational level by 
the enzymatic activity of SC proteases on human skin. 
Taken together, these studies help us to better understand the finely regulated balance 
of SC enzymatic activities and its functionality. The disturbance of SC proteolytic activities, 
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either caused by genetic defects or environmental influences, may compromise 
antimicrobial skin defense.  
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7. Appendix 
7.1 Abstract in German (Kurzfassung) 
Antimikrobielle Peptide sind ein wichtiger Teil des angeborenen Immunensystems der 
Haut. Epidermale Keratinozyten exprimieren eine Vielzahl verschiedener antimikrobielle 
Peptide, die eine schützende Barriere zu eindringenden Mikroorganismen bilden. Es 
wurde gezeigt, dass speziell das antimikrobielle Peptide S100A7c (Psoriasin) höchst 
effektiv gegen den humanpathogenen Keim Escherichia coli (E. coli) wirkt. Der genaue 
Mechanismus, der für die Regulation dieses antimikrobiellen Peptids in epidermalen 
Keratinozyten verantwortlich ist, war jedoch bis dato unklar. Deshalb untersuchten wir den 
Einfluss von verschiedenen mikrobiellen Bestandteilen auf die Expression von S100A7c. 
Wir konnten nachweisen, dass ausschließlich Flagellin, ein Ligand für Toll-like Rezeptor 
(TLR) 5, die Expression von S100A7c in primären humanen Keratinozyten stark 
induzierte, während alle weiteren TLR-Liganden keine Wirkung zeigten. Weiters konnten 
wir zeigen, dass hitzeinaktivierte Kulturüberstände von E. coli die mRNA- und 
Proteinproduktion von S100A7c stark induzierten. Im Gegensatz dazu hatte ein flagellin-
defizienter E. coli Stamm (∆FliC) keine induzierende Wirkung. Nun wollten wir 
untersuchen, ob auch hier die Signalweiterleitung über den TLR5 erfolgt. Durch 
Transfektion von TLR5 spezifischen siRNAs konnte die Expression dieses Rezeptors in 
Keratinozyten nahezu vollständig unterdrückt werden.  Nach darauffolgender Stimulation 
mit Flagellin oder hitzeinaktivierte Kulturüberstände von E. coli, konnten wir keine 
Induktion von S100A7c mehr feststellen. Wir konnten daher durch diese Serie von 
Experimenten nachweisen, dass das antimikrobielle Peptid S100A7c in primären humanen 
Keratinozyten über TLR5 Aktivierung induziert wird, und dass Flagellin der bakterielle 
Bestandteil ist, der für diese Induktion notwendig ist. 
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Ein weiteres antimikrobielles Peptid, das von humanen Keratinozyten produziert wird  
ist RNase 7. Diese RNase trägt nicht nur zur Oberflächenribonukleasetätigkeit der 
menschlichen Haut bei, sondern ist vielmehr auch ein wichtiger Faktor für die 
antimikrobielle Abwehr an der Hautoberfläche. Mittels RT-PCR konnten wir zeigen, dass 
zusätzlich zu RNase 7, auch andere RNasen (RNasen 1, 4 und 5) sowie ein RNase-
Inhibitor (RI) von humanen Keratinozyten produziert werden. RNase-Inhibitoren sind 
endogene Proteine, die die Aktivität von RNasen blockieren können. In vitro Experimente 
zeigten, dass dieser RI, sowohl die Ribonukleaseaktivität von Stratum corneum (SC) 
RNasen, als auch die antibakterielle Wirkung von RNase 7 und RNase 5 unterdrücken 
konnte.  
In vivo konnten wir eine starke Expression von RI in den granulären Schichten, jedoch 
nicht in der verhornten Schicht der Epidermis nachweisen. Weiters konnten wir zeigen, 
dass SC Extrakte in der Lage waren rekombinant hergestellten RI abzubauen. Dies konnte 
durch Zugabe von Aprotinin, welches die Aktivität von Serinproteasen inhibiert, verhindert 
werden. Diese Ergebnisse deuten stark auf das Bestehen physiologischer Mechanismen 
zum Abbau von RI im SC hin, wodurch sowohl die Ribonukleaseaktivität als auch die 
antimikrobielle Aktivität von RNasen an der Hautoberfläche gewährleistet werden kann. 
Zusammengefasst, konnten wir mit diesen Studien neue Einblicke in die Wirkungs- 
mechanismen und Regulation von antimikrobiellen Peptiden in der menschlichen Haut 
geben. Weiters konnten wir einen neuen wichtigen Aspekt der proteolytischen Aktivität von 
SC in der Haut demonstrieren. 
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7.2 Abbreviations 
CCL C-C chemokine ligand  
CF  Cystic fibrosis  
CFU colony-forming units 
CRAMP  cathelicidin-related antimicrobial peptide 
DNA   deoxyribonucleic acid 
ECP    eosinophil cationic protein 
EDN    eosinophil-derived neurotoxin  
EDTA   Ethylendiamintetraaceticacid 
GAS    group A Streptococcus  
hBD    human β-defensins 
hCAP-18  human cationic antimicrobial protein with a molecular size of 18 kDa 
HNP   human neutrophil peptides  
IFN   interferon  
IL    interleukin  
kDa   kilo Dalton 
LD90   lethal dose that achieves a CFU reduction of 90% 
LPS lipopolysaccaride 
LRR  leucine-rich repeat  
LTA  lipoteichoic acid  
MDP muramyl dipeptide  
mRNA  messenger RNA  
NLR (NOD)-like receptor 
NOD nucleotide-binding oligomerization domain  
PAMP pathogen-associated molecular pattern  
PMA    phorbol-myristate-acetate  
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PRR  pattern recognition receptors 
RI   ribonuclease inhibitor 
RNA   ribonucleic acid 
RNase  ribonuclease 
SC    stratum corneum 
siRNA   small interference RNA 
TLR    Toll-like receptor 
TNF    tumour necrosis factor  
VDR   vitamin D receptor  
VDRE   vitamin D response element 
∆FliC   flagellin-deficient 
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